Mississippi State University

Scholars Junction
Theses and Dissertations

Theses and Dissertations

5-5-2007

Determination of Enantiomeric Composition of Pharmaceutical
Compounds using Electrospray Ionization Mass Spectrometry
(ESI-MS)
Beibei Wang

Follow this and additional works at: https://scholarsjunction.msstate.edu/td

Recommended Citation
Wang, Beibei, "Determination of Enantiomeric Composition of Pharmaceutical Compounds using
Electrospray Ionization Mass Spectrometry (ESI-MS)" (2007). Theses and Dissertations. 1344.
https://scholarsjunction.msstate.edu/td/1344

This Graduate Thesis - Open Access is brought to you for free and open access by the Theses and Dissertations at
Scholars Junction. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of
Scholars Junction. For more information, please contact scholcomm@msstate.libanswers.com.

DETERMINATION OF ENANTIOMERIC COMPOSITION OF
PHARMACEUTICAL COMPOUNDS USING
ELECTROSPRAY IONIZATION MASS
SPECTROMETRY (ESI-MS)

By
Beibei Wang

A Thesis
Submitted to the Faculty of
Mississippi State University
in Partial Fulfillment of the Requirements
for the Degree of Master of Science
in Chemistry
in the Department of Chemistry

Mississippi State, Mississippi
May 2007

DETERMINATION OF ENANTIOMERIC COMPOSITION OF
PHARMACEUTICAL COMPOUNDS USING
ELECTROSPRAY IONIZATION MASS
SPECTROMETRY (ESI-MS)

By
Beibei Wang

Approved:

______________________________
Michael E. Koscho
Assistant Professor of Chemistry
(Director of Thesis)

______________________________
Andrzej Sygula
Associate Professor of Chemistry
(Committee Member)

______________________________
Stephen C. Foster
Associate Professor of Chemistry
(Graduate Coordinator)

______________________________
Philip B. Oldham
Dean of the College of Arts & Sciences

Name: Beibei Wang
Date of Degree: May 5, 2007
Institution: Mississippi State University
Major Field: Chemistry
Major Professor: Dr. Michael E. Koscho
Title of Study: DETERMINATION OF ENANTIOMERIC COMPOSITION OF
PHARMACEUTICAL COMPOUNDS USING ELECTROSPRAY
IONIZATION MASS SPECTROMETRY (ESI-MS)
Pages in Study: 117
Candidate for Degree of Master of Science

The work in this thesis has demonstrated the chiral recognition through the
adaptation of chromatographically derived chiral recognition systems by electrospray
ionization mass spectrometry (ESI-MS). Mass-labeled, pseudoenantiomeric chiral
selectors (where each pseudoenantiomer had the opposite stereochemistry, but was
slightly different in mass due to labeling of one enantiomer) were prepared as soluble
analogues of Pirkle type chiral stationary phases. When mixed with a chiral analyte,
solutions containing these pseudoenantiomeric selectors afforded selector-analyte
complexes in the ESI-MS, and the relative peak intensities of the complexes could be
related back to the enantiomeric composition of the analyte. In each case of this study, the
complex intensity fraction for either of the selector-analyte complexes in the ESI-MS
varies linearly with the enantiomeric composition of the analyte. This linear relationship
provides a measure of the extent of enantioselectivity and allows quantitative analysis of
the enantiomeric composition of analyte.
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CHAPTER I
INTRODUCTION

Stereochemistry
Stereochemistry (from the Greek stereos, meaning solid) is the study of the three
dimensional structures of molecules. Since most molecules are three dimensional,
stereochemistry, in fact, pervades all of chemistry [1].
To some extent, the history of stereochemistry begins in 1809 when the French
physicist Malus [2] discovered plane-polarized light. In 1815, Biot [3] performed
experiments using plane-polarized light to organic substances: both liquid (such as
turpentine) and solutions of solids (such as sucrose, camphor, and tartaric acid). The
phrase “optically active” was applied to substances capable of rotating the plane of
polarization of plane-polarized light [1]. Then, this specific property of nature gained
considerable importance in the many fields, such as the sugar industry, analytical
chemistry, and the pharmaceutical industry.
The first separation of two optically active components was reported in 1848 by
Louis Pasteur [3]. In his work, he successfully resolved (separated) an optically inactive
substance (tartaric acid) into two components with different optically active properties by
1

the use of a magnifying glass and tweezers. Each of the optically active components had
the same physical properties as tartaric acid (such as density, melting point, solubility, etc.)
except that one of the components rotated the plane of polarization of plane-polarized
light clockwise while the other component rotated the plane of polarization of
plane-polarized light by the same amount counterclockwise. Based on his research,
Pasteur made a proposal that still stands as the foundation of stereochemistry: the two
components separated from tartaric acid were mirror images of each other! Furthermore,
he advanced the field and introduced the technique of resolution by diastereoisomer
formation [4]. This technique of resolution is the basis of many modern separation
methods, especially chromatographic separations.
In 1874, the Dutch physical chemist Jacobus Hendricus van’t Hoff [5] and the
French chemist Achille Le Bel [6] independently explained optical activity in terms of the
tetrahedral arrangement of the atoms bound to carbon. In 1894, Fisher [7] identified the
16 stereoisomers for the aldohexoses (C6H12O6), which was considered as one of the most
remarkable works in the history of chemistry. In 1975, Prelog won the Nobel Prize in
chemistry due to his great work in the stereochemistry of alkaloids, antibiotics, enzymes,
and other natural compounds. He designed the stereochemical distinctions broadly used
today for mirror image configurations: Z/E for geometric isomers and R/S designations
for enantiomers.

2

Since its realization as a fundamental property in nature by Pasteur in 1848,
chirality became more and more significant in inorganic chemistry, organic chemistry,
physical chemistry, biochemistry and many other fields. The term chiral (from the Greek
cheir, “hand”) is used to designate an object which is non-superimposable on its mirror
image. In terms of chemistry, these objects are molecules. Enantiomers, derived from the
Greek word "enantio" meaning opposite, are non-superimposable mirror image molecules
(Figure 1.1). A mixture of equal amounts of the two enantiomers is said to be a racemic
mixture. Because they possess identical physical properties (such as density, melting
point and boiling point), they are often viewed as a single entity.

Cl

~C~H

H~Br

BrJII""'"

F

\

F

Figure 1.1: A molecule and its non-superimposable mirror image.

Enantiomers can exhibit distinct chemical behavior when subjected to a chiral
environment. Because of chirality, living organisms may show different biological
responses to one of a pair of enantiomers [8]. For example, as a nonsteroidal
anti-inflammatory medication, ibuprofen contains therapeutic activity only in the (+)
3

isomer; our bodies can utilize only (-) amino acids but not (+) amino acid; (+) leucine
tastes sweet and (-) leucine tastes bitter. An infamous example of the significance of
stereochemistry on human health is the thalidomide disaster [9]. First prepared in 1957 in
Germany, thalidomide (Figure 1.2) was a sedative and hypnotic drug that was widely
prescribed to alleviate morning sickness. However, it was discovered that one enantiomer
of the drug was safe while the other had teratogenic effects, causing serious genetic
damage to early embryonic growth and development.

O
H
O

N

O

O
N
H

O

O

(S)-Thalidomide
Teratogen

N
H

O
N

H
O

(R)-Thalidomide
Sedative

Figure 1.2: Enantiomers of thalidomide.

In 1992, the U.S. Food and Drug Administration (FDA) issued a guideline for
chiral drugs that only its therapeutically active isomer can be brought into market;
moreover, each enantiomer of the drug should be tested separately for its
pharmacological and metabolic pathways [10]. In 2000, single isomer drug sales reached
$133 billion worldwide, increased by more than 13% from 1999 and accounting for 32%
of total drug sales [11]. In 2003, nine of the ten top-selling drugs, which were accounting
4

for approximately 50 billion US$, were derived from chiral materials, six of these were
sold in single enantiomer form [12].

Traditional Methods for Enantiomeric Excess Determination
Enantiomeric excess (ee) is defined as a measurement for how much of one
enantiomer is present compared to the other. The need to obtain enantiomerically pure
products pushed analytical as well as synthetic chemists to develop and improve the
technologies for analysis and separation of racemic compounds. There are various
methods for enantiomeric analysis of a chiral compound, such as polarimetry, nuclear
magnetic resonance (NMR), chiral chromatography (including GC, LC, HPLC etc.),
circular dichroism (CD), chiral sensor techniques, and mass spectrometry [13].
Polarimetry is the method using the optical activity of a chiral molecule to
analyses the enantiomeric composition. The plane of polarization of plane-polarized light
will be rotated to either right (clockwise) or left (anticlockwise) by the chiral component
in the solution when the plane-polarized light passes through the solution chamber. The
clockwise rotation is designated as (+), while the anticlockwise rotation is designated as
(-). Nowadays, although advanced polarimeters have been developed with advanced
digital technology, this traditional method is no longer popular.
NMR is a very popular technique for rapid analysis of the enantiomeric
composition. Because enantiomers cannot be discriminated in an achiral environment, for
5

the determination of the enantiomeric composition by means of NMR techniques,
nonracemic chiral auxiliaries are needed to convert the isochronous enantiotopic nuclei
into anisochronous diastereotopic nuclei [14]. As long as there is a large enough chemical
shift nonequivalence ∆δ (diastereomeric shift dispersion), integration will be able to give
a direct measure of the diastereomeric composition of the sample [15]. Subsequently, the
data can be related back to the enantiomeric composition. Cram and co-workers firstly
reported this application in NMR in 1959 [16].
There are three types of commonly used chiral auxiliaries: chiral solvating agents,
chiral lanthanide shift reagents, and chiral derivatizing agents [15]. Since 1967, when
Pirkle [17] reported the application of chiral solvating agents in the enantiomeric analysis
by NMR, chiral auxiliaries have found widespread use. A chiral environment can be
formed when using a chiral solvating agent and enantiomers in solution can be
subsequently distinguished by observing the different chemical shift of nonequivalence
nuclei. Similar to the chiral solvating agents, chiral lanthanide shift reagents also form
diastereomeric complexes with the analyte so that they allow a direct determination of the
enantiomeric composition [18]. The application of chiral derivatizing agents requires the
formation of diastereomers before the NMR analysis. In principle, the sample can serve
as its own chiral probe [19], sometimes allowing quantification under strictly defined
conditions. Of course, one major drawback to this method is the requirement for the
derivatization before the analysis.
6

Another popular enantiomeric analysis method is chromatography, which mainly
includes Gas Chromatography (GC), Liquid Chromatography (LC), and High
Performance Liquid Chromatography (HPLC). Since the 1930’s LC methods have been
used to an increasing extent for enantiomeric excess determinations. In 1959 Karagunis
and Lippold [20] reported the separation of the racemic mixtures of butan-2-ol and of
2-bromobutane on optically active stationary phases using GC methods. Seven years later,
the first example of a fully reproducible separation of enantiomers by means of GC on a
chiral stationary phase (CSP) was reported by Gil-Av and coworkers [21].
Compared to GC, the HPLC method is superior in its versatility and wider range
of application, since the analysis of diastereomer mixtures by GC is only applied to
volatile and relatively stable compounds. HPLC also provides fast and accurate methods
for chiral separation, and allows on-line detection of both optical rotation and mass of
enantiomers if appropriate detection devices are connected [22, 23]. Since the first report
of the use of a chiral HPLC chromatographic separation with silica gel support by Klem
and Reed [24] in 1960, chiral HPLC has been considered to be one of the best methods
for the direct separation and analysis of enantiomers.
There are two current chiral HPLC methods: direct and indirect. The direct chiral
HPLC method uses chiral stationary phases (CSPs) or chiral additives in the mobile
phase to induce the formation of the transient diastereomeric complexes, while the
indirect method utilizes the derivatization of samples [25]. The chiral mobile phase
7

additives are used for the analysis of many types of chiral compounds, such as amino
alcohols, sulfoxides, glycols, hydroxyl ketones, and hydroxyl carboxylic and amino acids.
Although the use of chiral additives in the mobile phase is simple and sensitive, their
application is limited because of the relatively high cost of the chiral reagents.
Direct chiral separations using CSPs are more widely used than chiral additives in
the mobile phase or the indirect method [26]. Same as the use of chiral additives in the
mobile phase, the separation of enantiomers by chiral HPLC stationary phases is also
based on the formation of transient diastereomeric complexes. When enantiomers of a
chiral compound pass through the CSPs in HPLC, transient diastereomeric complexes are
formed between the enantiomers and the chiral molecule which is an integral part of the
chiral stationary phase. If the energy difference for the association and dissociation of the
complexes are large enough, their retention time must be different. Consequently, a
separation will be observed. There are several possible interactions between the analyte
and CSP, including π-π interaction, hydrogen bond, inclusion complexation, dipole-dipole
forces, and hydrophobic interaction.
Nowadays, there are hundreds of commercially available CSPs for HPLC. Based
on the type of analyte-CSP complexes formed, Wainer designated five major classes of
HPLC-CSPs: (1) Pirkle type, in which the analyte-CSP complexes are formed by
attractive-repulsive interactions, mainly by electron donor-acceptor mechanisms; (2)
cellulose derivatives, which involves attractive interactions followed by inclusion into
8

chiral cavities; (3) cyclodextrins and crown ethers, which form inclusion complexes; (4)
the analyte is a part of a diastereomeric metal complex; (5) proteins, where the
analyte-CSP complexes are based on the combination of hydrophobic and polar
interactions. Pirkle type CSPs are probably the most important and wildly used. Pirkle’s
group at the University of Illinois is generally acknowledged as the first inventor of this
type of CSP. They have advanced this area by developing amino acid derivatives
containing π-acidic or π-basic aromatic groups that are ionically or covalently linked to a
silica support.

(a)
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OH
O Si
OH

NO2
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H H
NH3+ O2C -C N C
Ph
O
I

NO2

II

NO2
(b)

OH
O Si
OH

0- -·~
I

O H H
N
C
N C
H Ph
O

NO2

Figure 1.3: Type 1 CSP Pirkle N-(3,5-dinitrobenzoyl)phenylglycine (a) ionically or (b)
covalently bonded to a aminopropylsilica.

As mentioned above, several interactions can explain the formation of Pirkle type
analyte-CSP complexes: (1) π-π interactions between the π-donor and π-acceptor; (2)
hydrogen bonding interaction; (3) dipole-dipole moment interactions; and (4) steric
interactions arising from the bulky non-polar groups attached near the chiral center of the
9

CSP providing conformational control. Figure 1.3 shows a Pirkle type CSP of
N-(3,5-dinitrobenzoyl) phenylglycine ionically/covalently bonded to a silica support.
Pirkle type CSPs can separate the enantiomers of a wide range of racemic
compounds, such as alkyl and aryl carbinols, aryl substituted hydantoins, lactams,
succinamides, phthalides, sulfoxides, sulfides, amides and imides. However, some
analytes could overreact with the CSPs due to their structures containing many polar
functional groups (such as amino, carboxyl, and hydroxyl). These racemic analytes must
be converted to less polar counterparts by derivatization. In 1992, Pirkle [27] developed a
hybrid chiral column with both π-acid (3,5-dinitrobenzoyl) and π-base (naphthyl) groups.
This kind of column can resolve a variety of compounds, including carboxylic acids, a
very polar functional group, without initial derivatization.
In general, the chromatographic methods are sensitive, precise and reproducible.
Moreover, the enantiomeric analyses by chromatographic methods can be applied to a
broad range of compounds. Although chromatographic methods are considered to be
relatively fast, when it comes to screening of a large library, the method is relatively slow
because the time required for each single analysis. The columns for the chromatographic
methods are usually expensive, and not always efficient with complex mixtures. In
addition, they lose resolving power with time [28]. So there is still a need for a faster
method of analysis, especially in combinatorial synthesis or screening of a large library.
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Circular dichroism (CD) spectroscopy is one of the techniques employed for
distinguishing enantiomers. Hybrid methods which combine circular dichroism (CD)
spectroscopy and other traditional measurements are newly developed efficient and
simple methods for the enantiomeric excess determination. Examples include the UV-CD
method and the HPLC-CD method. The UV-CD method is simple to apply and requires
no additional information to determine the enantiomeric excess of various compounds.
The HPLC-CD method involves the use of CD spectra together with HPLC equipped
with a non-chiral stationary phase. When enantiomers are very difficult to separate by
HPLC or GC using common chiral columns, both of the methods (UV-CD or HPLC-CD)
are possible solutions to the determination of enantiomeric excess [29].

Mass Spectrometry Methods for Enantiomeric Excess Determination
Mass Spectrometry (MS) is not typically considered as a method that can
distinguish the enantiomers of an analyte because both enantiomers of the analyte will
afford identical mass spectra under the same experimental conditions [30]. However,
chiral molecules can be distinguished and even quantified by MS by the addition of
another chiral compound (chiral selector), followed by the generation of charged
diastereomeric complexes in the gas phase by an appropriate ionization method. The
developments of methods that utilize only mass spectrometry for the determination of
enantiomeric composition and the investigation of chiral recognition systems have been
11

given tremendous attention in recent years [31-34]. In the MS method, chiral information
can be introduced in a variety of ways to measure ee, but all rely upon the creation of
diastereomers or diastereomeric interactions. The first detection of a chirality-dependent
effect on mass spectrometry was reported by Fales et al. in 1977 [35], and since that time
MS methods have been widely studied.
Usually the traditional methods, such as HPLC, are slow when screening a large
library. However, MS has the potential to rapidly analyze large libraries since only a few
seconds are needed for each sample. In addition, MS has wide analyte scope (many
different types of molecules can be detected without the need for a chromophore), great
intrinsic sensitivity and tolerance to impurities (peaks other than the masses of interest
can be ignored). These properties, plus the potential of rapid analyses, make the MS
methods more and more attractive [32, 36].
Figure 1.4 illustrates basic strategies for chiral analysis by MS. Diastereomers are
generated in these MS experiments. The formation and/or dissociation of diastereomeric
complexes between a chiral selector molecule ((R)-SO) and enantiomeric selectands
((R)-SA and (S)-SA) have their respective binding constants (K). If these equilibria are
sufficiently discriminated by these binding constants, then (R)-SO is capable of
discriminating between the analyte enantiomers and said to be enantioselective. In this
simplified case, the effects of solvent and desolvation are not considered [37].
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Figure 1.4: Basic strategies for chiral analysis by MS method. If Ka,(R) ≠ Ka,(S) and/or Kd,(R)
≠ Kd,(S), then (R)-SO is enantioselective for the SA enantiomers [37].

The Ion source and the mass analyzer are the two main parts of a mass
spectrometer. The ion sources of original mass spectrometers couldn’t produce stable
molecular ions. Techniques such as chemical ionization (CI), field desorption, secondary
ionization MS (SIMS), plasma desorption, and laser desorption MS were introduced in
the 1960’s and 1970’s. In the 1980’s, other soft-ionization techniques such as fast atom
bombardment (FAB) [38], matrix-assisted laser desorption ionization (MALDI) [39-41],
and electrospray ionization (ESI) [42, 43] were introduced. In the past 10-15 years, many
of these ion source techniques have been refined and extensively used. In 2002, Tanaka
and Fenn [39,44] won a piece of the Nobel Prize for their work of the implementation of
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MALDI and ESI sources to ionize and effectively study the behavior of large
biomolecules by MS.
The FAB technology was primarily developed by Michael Barber in the early
1980s for the ionization of species from a solid matrix [38]. Such ionization results from
the sputtering of a solid sample spot by an incident fast particle beam of atoms (usually
Ar or Xe). The sample spot is composed of analyte and matrix which is usually a small
organic molecule, such as glycerol, and homogenizing the sample spot and transferring
charge to the analyte. Subsequently, a secondary ion beam which is composed of matrix
and analyte ions is ejected from the surface and detected by the mass spectrometer.
During this process, analyte or complexed analyte ions stay largely intact and can be
observed in the mass spectrum. Sawada and coworkers [45, 46] firstly reported the chiral
molecular recognition and enantiomer discrimination by the FAB technology forming the
complex formation between chiral crown ether and carbohydrate selectors for the
analysis of amino acid ester enantiomers.
MALDI was introduced in the late 1980s by Karas and Hillenkamp [41], as well
as Tanaka et al. [39]. In such ionization, the analyte is homogenized in a solid spot
composed of a suitable matrix with vibrational absorption properties complementary to
an incident laser light beam of defined wavelength. A localized disintegration of the solid
solution occurs when irradiating due to excitation of the matrix, ejecting analyte
molecules and matrix ions into the gas phase. Upon charge transfer and/or cation
14

attachment, the matrix molecules evaporate, so the analyte ions can be detected by the
mass spectrometer. The instrumental setups of FAB and MALDI are similar. For the case
of MALDI, the particle beam is replaced with an incident laser. As a developing
technology, MALDI will come to light in the near future, especially in the use for the
ionization of large bioorganic molecules [37].
By far, ESI pioneered by Fenn and coworkers [47] in 1984 is considered to be the
most popular ionization technique for generation and analysis of noncovalent complexes
by MS. This technique can be used for a broad range of molecules and complexes from a
flowing liquid stream. In 1991, Henion and coworkers demonstrated the first the analysis
of noncovalent complexes by ESI-MS [48].
Figure 1.5 shows a simplified depiction of ESI process: ionization is achieved by
the application of a high voltage (usually 3-5 kV) to a spray capillary through which the
sample solution is passed. Droplets, in the form of a Taylor cone [49], are emitted into the
spray chamber at the end of the capillary. Due to the solvent evaporation and “coulombic
explosion”, the droplets disintegrate and release charged ions of the analyte or complex
into the gas phase. Then, these ions are transferred into the high vacuum chamber for
mass analysis. Once transferred to the gaseous phase, these ions can be isolated and
analyzed by a number of techniques, such as collisional and radiative dissociation, to
study intrinsic binding properties in the absence of solvent [50]. Typically, ESI-MS based
enantiomeric discrimination techniques generate pairs of diastereomeric complexes
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before employing gas-phase dissociative or exchange processes for obtaining relative
quantitative information (enantioselectivity and ee determination) by MSn.
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Figure 1.5: Schematic depiction of an ESI source [37].

The evolution of mass analyzers, paralleling the development of ion sources, is
equally important to the study of diastereomeric complexation by MS. From the first
application of the quadrupole and quadrupole ion trap (QIT) in the 1950’s by Wolfgang
Paul [51], to the introduction of Fourier transform ion cyclotron resonance (FTICR) and
the use of MS/MS in the 1970’s, mass analyzers have emerged from instruments of rare
academic investigation to fully commercial availability [37].
The methods of chiral recognition by MS can be divided into two main groups.
One relies on the formation of mass-labeled, covalent diastereomers, and the other relies
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on non-covalent diastereomers that are formed by the analyte and the appropriate chiral
selector(s) [59]. The first method, covalent complexation, relies on an additional
derivatization step where kinetic resolution between the analyte and a mixture of
mass-labeled chiral derivatizing reagents (where each pseudoenantiomer has the opposite
stereochemistry, but a slightly different mass due to labeling of one enantiomer at a
remote position from the chiral recognition site) could be observed. As long as kinetic
resolution is observed in the derivatization step, the relative amounts of the derivatives
can be related back to the enantiomeric composition of the analyte [53-55]. Of course,
one major drawback to this method is the requirement for the preparation of derivatives
before the analysis.
The methods which rely on non-covalent complexation between analyte and
selector(s) are developed by two different groups: one uses a single-stage mass
spectrometric measurement, and the other one uses tandem mass spectrometry (MS/MS).
Up to now, tandem mass spectrometry (MS/MS) methods for the determination of
enantiomeric composition are the most popular. The MS/MS methods typically rely on
isolating a specific ion and allowing this ion to react with another reagent, or observing
the collision-induced dissociation (CID) of the complex, i.e. the ionized complex formed
in the first stage MS is isolated and guided into the second stage mass, where it will
exchange with another reagent to form a new species or undergo the collision-induced
dissociation (CID). Cyclodextrin-analyte complexes [52, 56] and chiral crown
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ether-chiral ammonium cation complexes [57] are the first examples to which the tandem
measurements have applied. When a pair of pseudodiastereomeric complexes between
the chiral references and enantiomer of analyte undergoes CID, both the peak intensities
of daughter ions and mother ions can be observed. The chiral recognition can be obtained
by measuring the ratio of these two peak intensities. Furthermore, a quantitative analysis
of analyte can be conducted using a calibration curve constructed by performing two CID
experiments with at least two mixtures with known enantiomeric composition.
In the case of single-stage MS, chiral host and chiral guest molecules are mixed in
solution and injected into the ion source for ionization, where diastereomeric complexes
are observed in the gas phase. Since the association constants of two diastereomeric
complexes are not equal, the peak height (different ion count) can be related back to the
enantiomer composition in solution phase if it is assumed that each diastereomer has the
same ionization efficiency. Due to the identical mass of diastereomeric complexes
between the host and analyte molecules, two injections are required for a complete chiral
recognition: one is for the solution containing the enantiomeric pure host molecule and
one of the enantiomers of the analyte; the other is for the solution containing the same
enantiomeric pure host molecule and another enantiomer of the analyte. To diminish the
fluctuating conditions, an internal standard is usually applied in each injection, and
according to the peak intensity of the internal standard, the desired peak can be
normalized.
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An alternative way is to label one of the enantiomers in such a way that the
diastereomeric complexes will appear at different mass in the mass spectrum. To achieve
this, a solution of pseudoenantiomeric chiral selectors (where each enantiomer is
mass-labeled at a remote site) has been utilized. Theoretically, the relative ratio of peak
intensities will change with the enantiomeric composition of analyte, so that the relative
intensities of pseudodiastereomeric complexes should represent the chiral recognition
effect of the chiral selectors to the analyte. That is, when pseudoenantiomeric chiral
selectors are applied, the enantiomeric compositions of the analytes are distinguishable
dependent on the relative intensities (i.e. peak height) of the non-covalent selector-analyte
complexes in the mass spectrum.
Dr. Michael Koscho’s research team has demonstrated a method using
Electrospray Ionization Mass Spectrometry (ESI-MS) to be capable of enantiomer
recognition [58-60]. The chiral recognition by this method is initially reported through
the utilization of chromatographically derived chiral recognition systems. In these cases,
soluble analogues of Pirkle type CSPs [61, 62] are used as pseudoenantiomeric chiral
selectors. In each solution, non-covalent complexes are formed between the Pirkle type
pseudoenantiomeric chiral selectors and the analyte whose enantiomers are known to be
resolved on the corresponding CSP. These complexes are transferred to the gas phase
using ESI-MS where each selector-analyte complex corresponds to a different peak in the
mass spectrum (Figure 1.6). Assuming that each complex transfers with the same
19

efficiency, the relative intensities of the (R)-selector-analyte complexes compared to the
(S)-selector-analyte complexes depend on the original enantiomeric composition of the
analyte in solution.

{'P'R•AR)+
('P'R•As)+

m/z
ΨR, ΨS = pseudoenantiomeric chiral selectors
AR, AS = analyte enantiomers

peaks of selector-analyte
complexes

Figure 1.6: Selector-analyte complexes correspond to different peaks in ESI-MS.

This method requires the development of appropriate pseudoenantiomers. The
molecular weight of each of the chiral selectors must differ so that each selector-analyte
complex will correspond to different peaks in the mass spectrum. A set of
pseudoenantiomers must show enantioselective interaction with the analyte. Since mass
spectrometry only detects charged species, selector-analyte complexes must also be easily
ionized through ESI and stable enough during the data collection. In addition, all changes
to molecular structure to achieve ESI-MS compatibility must occur far away from chiral
recognition sites.
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Figure 1.7: Structure of chiral selector (S)-1, (R)-2 and analyte 3.

For example, the mass-labeled soluble analogues of the tertiary amine appended
derivatives of N-(3,5-Dinitrobenzoyl)leucine, (S)-1 and (R)-2, which differ only by the
length of the N-alkyl chain of the amide, were reported as chiral selectors by Dr. Koscho
[58]. When chiral selectors (S)-1 and (R)-2 were mixed with analyte 3 (Figure 1.7) and
excess ammonium chloride, the following complexes: [1 + 3 + H]+ and [2 + 3 + H]+ were
be observed in the ESI-MS (Figure 1.8) [58].
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Figure 1.8: ESI-MS of a solution of pseudoenantiomeric chiral selectors (S)-1 and (R)-2
(1.0 mM each), racemic analyte 3 (1.0 mM), and ammonium chloride (10 mM)
in methanol/water (1:1) [58].

As mentioned above, peak intensities of selector-analyte complexes vary with
enantiomeric composition of analyte. Figure 1.9 shows the portions of the mass spectra
that contain the selector-analyte complexes obtained at three different enantiomeric
compositions of analyte 3 with chiral selector 1 and 2. The chiral recognition is clearly
demonstrated by the difference between the relative intensities of the selector-analyte
complexes. As the amount of (R)-3 is increased in the sample, the complex with the (R)-1
selector is increased relative to the complex with the (S)-1 selector. On the other hand, as
the amount of (S)-3 is increased in the sample, the complex with the (S)-1 selector is
increased relative to the complex with the (R)-2 selector. The sense of chiral recognition
is consistent with what is observed chromatographically [58].
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Figure 1.9: Partial ESI-MS of solutions containing pseudoenantiomeric chiral selectors
(S)-1 and (R)-2 (1.0 mM each), analyte 3 (1.0 mM), and ammonium chloride
(10 mM) in methanol/water (1:1). Spectra: (a) 79.6% enantiomeric excess
(R)-3, (b) racemic 3, and (c) 81.8% enantiomeric excess (S)-3 [58].

According to the work done by Dr. Koscho, the complexes between the two
pseudoenantiomeric chiral selectors and the chiral analyte can be observed in the ESI-MS
spectrum and the complex intensity fraction (CIF) of these complexes can be related back
to the enantiomeric composition of the analyte. The CIF is defined as the intensity of one
selector-analyte complex divided by the sum of the intensities for both selector-analyte
complexes. Shown in Figure 1.10 are the solution-phase equilibria between the
pseudoenantiomeric chiral selectors and the enantiomers of the analyte. Because two
pseudoenantiomeric chiral selectors are assumed to act as enantiomers, KRR equals KSS
and KSR equals KRS [58].
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Figure 1.10: The solution-phase equilibria between the pseudoenantiomeric chiral
selectors and the enantiomers of the analyte.

In general, given pseudoenantiomeric chiral selectors, ΨR and ΨS, and analyte
enantiomers, AR and AS, the enantioselectivity in solution, α, will be given by any of the
ratios of equilibrium constants shown in Equation 1.1. Of course, this assumes that the
pseudoenantiomeric chiral selectors are acting as enantiomers, and [ΨR] equals [ΨS] in
solution at beginning.

α=

KRR
KSR
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=

KSS
KRS

Equation 1.1

Assuming that in ESI-MS each complex transfers into the gas phase with the
same efficiency, the expression of the CIF is shown in Equation 1.2. The notation (Ψ·A)+
is an ion count of the corresponding selector-analyte complex, and [X] is a solution
concentration of component X. In this case, the CIF is expressed as the (R)-selector
analyte complex divided by the sum of the intensities for both selector-analyte
complexes.

CIF =

=

=

(ΨR·AR)+ + (ΨR·AS)+
(ΨR·AR)+ + (ΨR·AS)+ + (ΨS·AR)+ + (ΨS·AS)+
[ΨR·AR] + [ΨR·AS]
[ΨR·AR] + [ΨR·AS] + [ΨS·AR] + [ΨS·AS]
KRR[ΨR][AR] + KRS[ΨR][AS]

KRR[ΨR][AR] + KRS[ΨR][AS] + KSR[ΨS][AR] + KSS[ΨS][AS]

Equation 1.2

Equation 1.2 can be rearranged to afford Equation 1.3 [58]. This equation predicts
that the plot of the CIF versus the enantiomeric composition of the analyte (XR in this
case, the mole fraction of the (R)-analyte) is linear. This calibration curve can be used for
subsequent quantitative analysis of enantiomeric composition.

CIF =

α-1
α+1

(-)

XR +
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1
α+1

(-)

Equation 1.3

Additionally, the magnitude of the slope of the plot provides a measure of
enantioselectivity, that is, the relative affinity of one pseudoenantiomer selector molecule
for each enantiomer of the analyte.

Objective
This thesis focuses on development new Pirkle type pseudoenantiomeric chiral
selectors which can be used in the analysis of enantiomeric composition by ESI-MS. Two
kinds of Pirkle type pseudoenantiomeric chiral selectors which can be used to analyze
specific pharmaceuticals (such as naproxen and propranolol) are synthesized and
evaluated as chiral selectors using the ESI-MS method. In addition, since the tertiary
amine appended derivatives of N-(3,5-Dinitrobenzoyl)leucine were successfully used in
an enantiomeric analysis, the synthesis and evaluation of the corresponding quaternary
ammonium salts as chiral selectors using ESI-MS are discussed in this thesis.
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CHAPTER II
QUATERNARY AMMONIUM SALT APPENDED DERIVATIVES OF
N-(3,5-DINITROBENZOYL)LEUCINE AS CHIRAL SELECTORS
FOR ENANTIOMER ASSAYS BY ESI-MS

Introduction
Previously, Dr. Koscho reported the use of tertiary amine appended
N-(3,5-dinitrobenzoyl)leucine derivatives, 1 and 2, as pseudoenantiomeric chiral
selectors for enantiomer analyses by electrospray ionization mass spectrometry. These
chiral selectors were derived from the well-known chiral stationary phase DNB-leucine
and designed to remove the ionization site from the sites required for effective chiral
recognition [58]. As we mentioned in Chapter I, effective chiral recognition of these
chiral selectors in the electrospray ionization mass spectra was observed.
The appended tertiary amine portion in chiral selectors 1 and 2 is not significant
for chiral recognition purpose, but it allows ionization of the chiral selectors and any
complexes derived via protonation. However, in order to observe the significant peaks of
selector-analyte complexes, ESI-MS conditions have to be finely tuned to maintain the
stability of complexes during the analysis. It is necessary to add ionization additives such
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as weak acids (formic acid, acetic acid), or some salts (lithium chloride, ammonium
chloride) to ease of ionization. The excess additive to the solution to be assayed should
protonate the tertiary amine portion, affording high ion counts for the selector in the
electrospray ionization mass spectrum.
But it is unclear whether there are any side effects to the chiral recognition caused
by the large excess (usually 10 times to the selector and analyte) of additive. It is
interesting to find out if the enantioselectivity of a selector will be improved or impaired
if the large excess of additive is not present. Herein, quaternary ammonium salt appended
derivatives of N-(3,5-Dinitrobenzoyl)leucine 4 and 5 (Figure 2.1) are designed and used
as pseudoenantiomeric chiral selectors for Enantiomer Assays by ESI-MS, in which the
addition of excess weak acid or salt can be skipped.
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Figure 2.1: Structures of quaternary ammonium salt appended derivatives of
N-(3,5-Dinitrobenzoyl)leucine 4, 5, and analytes 3, 14.
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I

A quaternary ammonium salt is a kind of compound containing a nitrogen atom
with four attached groups, in which the nitrogen atom must carry a positive charge. The
synthesis and evaluation of quaternary ammonium salt appended derivatives of
N-(3,5-Dinitrobenzoyl)leucine as pseudoenantiomeric chiral selectors for enantiomer
analyses by ESI-MS as well as the enantioselectivity of these new chiral selectors
compared with the use of tertiary amine appended N-(3,5-dinitrobenzoyl)leucine
derivatives 1 and 2, using analytes 3 and 14 (See Figure 2.1), is discussed in this chapter.

Experimental
Chemical reagents were obtained from Aldrich Chemical Co. and used without
further purification. Dichloromethane (CH2Cl2) was dried over CaH2 and freshly distilled
before use. Tetrahydrofuran (THF) was dried over potassium metal and freshly distilled
before use. 1H NMR and

13

C NMR spectra were recorded on a Bruker AMX-300

spectrometer operating at 300 MHz for 1H and 75 MHz for 13C. Analyte 14 was available
from previous research [58].
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Figure 2.2: Preparation of chiral selectors (S)-1 and (R)-2.

Preparation of compound 8 [63]
A mixture of L-Leucine 6 (2.0 g, 15.2 mmol) and 3,5-dinitrobenzoyl chloride (3.9
g, 16.9 mmol) was dissolved in 50 mL of freshly distilled tetrahydrofuran in an
oven-dried round bottom flask. Propylene oxide (3.2 mL, 45.7 mmol) was added via
syringe. The reaction mixture was stirred at room temperature for 24 hours, and then
filtered. The solvent of the filtrate was removed by rotary evaporation under reduced
pressure to afford 4.16 g (12.8 mmol, 84%) of white solid. The product was used without
further purification.
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Preparation of compound 9 [63]
9 was prepared using the same procedures as described above with 80% yield
starting from 2.0 g (15.2 mmol) of D-Leucine. The product was used without further
purification.

Preparation of compound (S)-1 [58]
A mixture of 8 (650 mg, 2 mmol) and N-hydroxysuccinimide (230 mg, 2 mmol)
was dissolved in THF (15 mL) in an oven-dried round bottom flask. The mixture was
cooled in an ice-water bath to 0°C and the diisopropylcarbodiimide (DIC, 0.31 mL, 2
mmol) was added dropwise via syringe. The reaction mixture was stirred for 2 hours at
0°C, and then filtered to remove the precipitated urea by-product. The solvent was
removed by rotary evaporation under reduced pressure to afford a pale yellow solid (the
succinimide ester). This solid was then dissolved in acetonitrile (10 mL), cooled in an
ice-water

bath,

and

added

slowly

via

syringe

to

a

solution

of

the

N,N-diethyl-1,2-diaminoethane (0.56 mL, 4 mmol) in acetonitrile (10 mL) at 0°C. After
stirring for thirty minutes, the solvent was removed by rotary evaporation under reduced
pressure to afford a sticky solid. Flash chromatography using ethylacetate as the mobile
phase yielded 0.30 g (0.71 mmol, 36%) of yellow solid, m.p. 141-143 °C.
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1

H NMR (300 MHz, CDCl3): δ 9.14 (t, J = 2.0 Hz, 1H), 8.97 (d, J = 2.0 Hz, 2H),

7.91 (d, J = 6.1 Hz, 1H), 6.68 (m, 1H), 4.68 (m, 1H), 3.36 (m, 2H), 2.57 (m, 6H), 1.75 (m,
3H,), 1.04 (m, 6H), 1.00 (m, 6H).

13

C NMR (75 MHz, CDCl3): δ 173.1, 162.5, 148.4,

137.2, 127.8, 53.5, 51.9, 47.2, 41.3, 35.9, 25.0, 22.9, 21.7, 9.9. ESI-MS: 424 [M+H] +.

Preparation of compound (R)-2 [58]
(R)-2 was prepared using the same procedures as described above, starting from
650 mg (2 mmol) of 9 and 0.63 mL (4 mmol) of N,N-diethyl-1,3- diaminopropane with
41% yield (0.36 g, 0.82 mmol) of yellow oil.
1

H NMR (300 MHz, CDCl3): δ 9.23 (d, J = 2.0 Hz, 2H), 9.06 (t, J = 1.9, 1H),

8.53 (d, J = 6.0 Hz, 1H), 8.31 (m, 1H), 4.73 (m, 1H), 3.54 (m, 1H), 3.34 (m, 1H), 3.11 (m,
6H), 2.08 (m, 3H), 1.82 (m, 2H), 1.38 (m, 6H), 0.98 (m, 6H). 13C NMR (75 MHz, CDCl3):
δ 173.5, 162.8, 148.0, 137.1, 128.1, 120.5, 54.0, 49.4, 46.4, 40.5, 36.2, 24.9, 23.4, 22.8,
21.3, 8.4. ESI-MS: 438 [M+H] +.
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Figure 2.3: Preparation of analyte 3.

Preparation of compound (S)-3/(R)-3 [64]
L-Proline (1.00 g, 8.69 mmol) was dissolved in 22 mL of 2 M sodium hydroxide
in a 100 mL flask. The mixture was cooled to 0°C and benzoyl chloride (2.0 mL, 17.2
mmol) was added dropwise. The reaction mixture was stirred for an additional 2 hours at
0°C. The reaction mixture was acidified to pH 1, and then extracted with CH2Cl2 (3 × 30
mL). The combined organic layer was washed with water (3 × 30 mL) and dried over
anhydrous magnesium sulfate. The solvent was removed by rotary evaporation under
reduced pressure to afford 1.65 g (7.53 mmol) of white solid. The N-pivaloyl-proline was
used without further purification. 2.1 g (8.5 mmol) of 2-ethoxy-1-ethoxy-carbonyl-1,2dihydroquinoline (EEDQ) was added to a solution of 1.65 g (7.53 mmol) of 12 in 50 mL
CH2Cl2. The mixture was cooled to 0°C and 1.45 mL (11.5 mmol) of 3,5-dimethylaniline
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was added dropwise. The reaction mixture was stirred for an additional 1.5 hours at 0°C,
and then stirred for another 2 hours at room temperature. The reaction mixture was
washed with 2 M HCl (2 × 30 mL), 5% NaHCO3 (2 × 30 mL), and water (30 mL once),
and dried over anhydrous magnesium sulfate. The solvent was removed by rotary
evaporation under reduced pressure to afford 1.92 g (6.36 mmol, 73%) of white solid.
The (R)-3 was prepared in the same method starting with D-proline (1.00 g, 8.69 mmol).
1.84 g (6.08 mmol, 70%) of white solid was obtained.
1

H NMR (300 MHz, CDCl3): δ 8.76 (br s, 1H), 7.14 (s, 2H), 6.63 (s, 1H), 4.49 (m,

1H), 3.65 (m, 1H), 3.54 (m, 1H), 2.36 (m, 1H), 2.25 (s, 6H), 1.93-2.11 (m, 3H), 1.24 (s,
9H). 13C NMR (75 MHz, CDCl3): δ 180.9, 171.5, 139.5, 137.9, 125.7, 118.0, 60.7, 45.3,
38.9, 26.2, 24.3, 23.6, 20.3. ESI-MS: 303 [M+H] +.
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Figure 2.4: Preparation of compound (S)-4.

The preparation of quaternary ammonium salt (S)-4 [65]
106 mg (0.25 mmol) of (S)-1 was dissolved in acetone (10 mL) in a round bottom
flask, followed by the addition of iodomethane (156 µL, 2.5 mmol). The reaction mixture
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was stirred at 40°C for one hour, and then stirred at room temperature for 24 hours. The
solvent and excess iodomethane were removed by rotary evaporation under reduced
pressure to afford 136 mg (0.24 mmol, 96%) of yellow solid.
1

H NMR (300 MHz, CDCl3): δ 9.19 (t, J = 2.0 Hz, 1H), 9.02 (d, J = 2.0 Hz, 2H),

7.97 (d, J = 6.1 Hz, 1H), 6.77 (m, 1H), 4.64 (m, 1H), 3.67 (m, 2H), 3.44 (m, 9H), 1.78 (m,
3H,), 1.24 (m, 6H), 1.01 (m, 6H).

13

C NMR (75 MHz, CDCl3): δ 174.1, 163.0, 148.8,

136.7, 128.2, 121.3, 63.5, 55.7, 53.7, 44.3, 41.1, 36.2, 22.5, 21.6, 8.2. ESI-MS: 438 [M] +.

The preparation of quaternary ammonium salt (R)-5 [65]
(R)-5 was prepared using the same methylation and isolation procedures as
described above, from 109 mg of (R)-2 with 96% yield of yellow solid.
1

H NMR (300 MHz, CDCl3): δ 9.29 (t, J = 2.0 Hz, 1H), 9.12 (d, J = 2.0 Hz, 2H),

8.32 (d, J = 6.1 Hz, 1H), 8.07 (m, 1H), 4.70 (m, 1H), 3.51 (m, 2H), 3.29 (m, 9H), 2.08 (m,
3H,), 1.96 (m, 2H), 1.27 (m, 6H), 1.00 (m, 6H).

13

C NMR (75 MHz, CDCl3): δ 173.7,

164.1, 148.3, 136.5, 128.2, 120.9, 56.6, 52.3, 49.4, 44.8, 41.9, 40.5, 24.3, 22.6, 21.5, 8.3.
ESI-MS: 452 [M] +.

Preparation of solutions
Stock solutions of (R)-3, (Racemic)-3, and (S)-3 were prepared in methanol.
Different amounts of these three solutions were mixed to afford five stock solutions of
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analyte 3 at the concentration of 2 mM, each having the desired enantiomeric
composition: (a) 100% (R)-3, (b) 70% (R)-3 + 30% (S)-3, (c) 50% (R)-3 + 50% (S)-3, (d)
20% (R)-3 + 80% (S)-3, and (e) 100% (S)-3. Five stock solutions of analyte 14, each
having the having the desired enantiomeric composition: (a) 100% (R)-14, (b) 75%
(R)-14 + 25% (S)-14, (c) 50% (R)-14 + 50% (S)-14, (d) 25% (R)-14 + 75% (S)-14, and (e)
100% (S)-14, were prepared in the same way. The enantiomeric composition of each
stock solution was determined by HPLC (see below for HPLC conditions). 1:1 mole of
(S)-4 and (R)-5 were mixed and dissolved in methanol to afford the stock solution of
pseudoenantiomeric selectors at the concentration of 5 mM; the stock solution of
selectors (S)-1 and (R)-2 was prepared in the same way. The stock solution of ammonium
chloride was prepared in water at the concentration of 20 mM. The final solutions were
made by combining the calculated amount of the corresponding stock solutions of analyte,
pseudoenantiomeric selectors, and ammonium chloride (for tertiary amine appended
chiral selectors only), and diluting with methanol and water. The final concentration for
the solution containing chiral selectors 1 and 2 is 1.0 mM for 1 and 2, 0.2 mM for analyte,
and 10 mM for ammonium chloride in methanol/water (1:1). Likewise, solutions with a
final concentration of 1.0 mM for chiral selectors 4 and 5, 0.2 mM for analyte in
methanol/water (1:1) were prepared.
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Determination of enantiomeric composition of stock solutions of analyte 3 and 14 by
HPLC
High performance liquid chromatography (HPLC) was performed using the
system consisted of a Beckman System Gold Programmable Solvent Module 125 HPLC
pump, a Rheodyne 7725i injector with a 20-µL sample loop, a HP Hewlett Packard series
1050 UV detector operating at 254 nm and an SRI model 302 PeakSimple
Chromatography Data System six-channel recorder.
The chiral stationary phase DNB-leucine (4.6 × 250 mm column) was prepared by
literature methods [66]. All solvents used were HPLC grade and used without further
purification.
20 µL of each stock solution of analyte was injected into HPLC system. HPLC
conditions were as follows: mobile phase, 60% hexanes/38% isopropyl alcohol/2%
methanol; flow rate, 2 mL/min; column dimensions, 4.6 × 250 mm. The peak was
monitored with UV-detector at λ = 254 nm. Each solution was measured three times, and
the average value of these three tests was used as the enantiomeric composition of analyte
in the final solutions. The void time was determined by recording the retention time of
1,3,5-tri-tert-butylbenzene at the same condition.
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Mass spectrometry
All mass spectra were obtained on a Micromass Quattro Micro (Beverly, MA)
triple quadrupole mass spectrometer with electrospray ionization running in the positive
ion mode. Solutions were infused with a syringe pump into the ESI source at a rate of 20
µL/min. Spectrometer conditions were as follows: capillary voltage, 3.0 kV; Cone voltage,
12.0 V; extractor voltage, 1.0 V; RF lens, 0.5 V; source temperature, 80°C; desolvation
temperature, 325°C; cone gas flow, 71 L/h; desolvation gas flow, 608 L/h. For each
sample of direct infusion, a full scan required about 0.7 s. The data collected over a 1-min
period were averaged to afford the final spectrum.

Results and Discussion
The previous tertiary amine appended chiral selectors used in this study were
based on the soluble analogues of Pirkle type CSPs. According to the previous work done
by Dr. Koscho, the chiral selectors 1 and 2 were designed to (1) act as mass-labeled
pseudoenantiomers where both can be detected in a single mass spectrometric experiment
and (2) have the ionization site far from the positions required for chiral recognition [58].
As mentioned in chapter one, the primary interactions between these chiral selectors and
analytes 3 and 14 responsible for chiral recognition are (1) a π-stacking interaction
between the π-acidic dinitro aromatic ring of the selector and the π-basic dimethylanilide
ring of the analyte; (2) a hydrogen bond between the DNB amide proton of the selector
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and the carbonyl group of the analyte; and (3) a hydrogen bond between the electron-rich
C-terminal carbonyl group of leucine of the selector and the anilide proton of the analyte.
To diminish the effect of weak acid or salt additive in the ionization step, quaternary
ammonium salt appended derivatives of N-(3,5-Dinitrobenzoyl)leucine chiral selectors 4
and 5 are herein introduced, which still maintain the all the interactions with the analyte
we just mentioned. Since these quaternary ammonium salt chiral selectors are already
positively charged, the additive is no longer necessary. Like in the selectors 1 and 2, the
ionization site is still far away from the positions required for chiral recognition in the
new chiral selectors.
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Figure 2.5: ESI-MS of solutions containing pseudoenantiomeric chiral selectors 4, 5 and
analyte 3.
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A 1:1 mixture of the quaternary ammonium salt 4 and 5 was prepared and used as
the pseudoenantiomeric chiral selectors. The final solution was made to contain 1 mM of
each (S)-4 and (R)-5, and 0.2 mM of the analyte 3. The enantiomeric composition of 3 in
each solution was varied, which was determined by HPLC. In each case the solvent was a
1:1 mixture of methanol and water. Electrospray ionization was performed on the
solutions of chiral selector (S)-4 and (R)-5, and analyte 3 (see Figure 2.5). The positively
charged selector-analyte complexes were observed in the mass spectrometry. Figure 2.6
shows the total ion count (TIC) chromatogram. This spectrum was obtained by infusing
the sample into the spectrometer at a flow rate of 20 µL/min with a syringe pump. The
mass spectrum is extracted by averaging about 1 min of TIC.

Intensity
100

TIC

%

0

--~~~~~~~~~~~~~~~~~~

0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90 1.00
Time

mm

Figure 2.6: Total ion count chromatogram of a solution infused by a syringe pump.
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Figure 2.7 shows the full mass spectrum for the solution containing racemic
analyte 3 and chiral selector 4 and 5. The monomeric ions of analyte [3 + Na]+ and chiral
selectors, [4]+ and [5]+, are observed at m/z 325, 438, and 452, respectively. The iodided
homo-dimeric and hetero-dimeric ions are observed at m/z 1003 [42 + I]+, 1037 [52 + I]+
and 1017 [4 + 5 + I]+. The analyte-selector hetero-dimers, [3 + 4]+ and [3 + 5]+, are
observed at m/z 740 and 754 respectively.
452

100

[5]+

[4]+

438

%

[3+4]+

740
[3+Na]

+

[4+5+I]+

754

325

0

[3+5]+

[42+I]+

[52+I]+

1017
1003 1037
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Figure 2.7: Mass spectrum of a solution of pseudo-enantiomeric selectors 4 and 5 (1.0
mM) and analyte 3 (0.2 mM) in water/methanol (1:1).

Partial mass spectra of pseudo-enantiomeric selectors (S)-4 and (R)-5, and analyte
3 are shown in Figure 2.8. The enantiomeric compositions of analyte 3 in the five
solutions are as follow: (a) 100% (R)-3, (b) 71.09% (R)-3, (c) 50.45% (R)-3, (d) 19.40%
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(R)-3, and (e) 0% (R)-3. The relative intensities of the selector-analyte complexes vary
regularly with the enantiomeric composition of the analyte, clearly demonstrating chiral
recognition. As the amount of (R)-3 is increased in the sample, the complex with the
(R)-5 selector is increased relative to the complex with the (S)-4 selector (m/z 754 vs m/z
740); likewise, as the amount of (S)-3 is increased in the sample, the complex with the
(S)-4 selector is increased relative to the complex with the (R)-5 selector. The sense of
chiral recognition is consistent with what is reported previously using the chiral selectors
(S)-1 and (R)-2, where the intensity of the (R)-3 + (R)-5 ion (m/z 740) increased as the
increase of the analyte (R)-3, and the intensity of the (S)-3 + (S)-4 ion (m/z 726) increased
as the increase of the analyte (S)-3.
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Figure 2.8: Partial electrospray ionization mass spectrum of pseudoenantiomeric chiral
selectors (S)-4 and (R)-5 (1.0 mM each), analyte 3 (0.2 mM) in
methanol/water (1:1). The enantiomeric compositions of analyte 3 are as
follow: (a) 100% (R)-3, (b) 71.09% (R)-3, (c) 50.45% (R)-3, (d) 19.40% (R)-3,
and (e) 0% (R)-3.

To compare with the previous tertiary amine appended chiral selectors with the
addition of weak acid (here we use NH4Cl), the ESI-MS of chiral selector 1, 2 and
analyte 3 (Figure 2.9) was also performed in the same conditions as the chiral selector 4,
5 and analyte 3. A 1:1 mixture of 1 and 2 was prepared and used as the
pseudoenantiomeric chiral selectors. The final solution was made to be 1 mM of both
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(S)-1 and (R)-2, 0.2 mM of 3 and 10 mM of NH4Cl. The enantiomeric composition of 3
in each solution was the same as in the solutions of chiral selector 4 and 5. In each case
the solvent was a 1:1 mixture of methanol and water. This spectrum was obtained by
infusing the sample into the spectrometer at a flow rate of 20 µL/min with a syringe pump.
The mass spectrum was extracted by averaging about 1 min of TIC.
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Figure 2.9: ESI-MS of solutions containing pseudoenantiomeric chiral selectors 1, 2,
analyte 3 and NH4Cl.
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Figure 2.10: Mass spectrum of a solution of pseudo-enantiomeric selectors 1, 2 (1.0 mM),
analyte 3 (0.2 mM) and NH4Cl (10 mM) in water/methanol (1:1).

Figure 2.10 shows the full mass spectrum for the solution containing racemic
analyte 3 and chiral selector 1 and 2. The monomeric ions of analyte [3 + H]+ and chiral
selectors, [8 + H]+ and [9 + H]+, are observed at m/z 303, 424, and 438, respectively.
Analyte dimers and selector dimers are observed at m/z 605 [32 + H]+, 622 [32 + NH4]+,
883 [12 + 2H + Cl]+, 897 [1 + 2 + 2H + Cl]+ and 911 [22 + 2H + Cl]+. The
analyte-selector hetero-dimers, [1 + 3 + H]+ and [2 + 3 + H]+, are observed at m/z 726 and
740 respectively.
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Figure 2.11: Partial electrospray ionization mass spectrum of pseudoenantiomeric chiral
selectors (S)-1 and (R)-2 (1.0 mM each), analyte 3 (0.2 mM) and NH4Cl in
methanol/water (1:1). The enantiomeric compositions of analyte 3 are as
follow: (a) 100% (R)-3, (b) 71.09% (R)-3, (c) 50.45% (R)-3, (d) 19.40%
(R)-3, and (e) 0% (R)-3.

Partial mass spectra of pseudoenantiomeric selectors (S)-1 and (R)-2, and analyte
3 are shown in Figure 2.11. The enantiomeric composition of 3 in each solution was the
same as in the solutions of chiral selector 4 and 5. The relative intensities of the
selector-analyte complexes vary regularly with the enantiomeric composition of the
analyte, indicating chiral recognition. The intensity of the (R)-3 + (R)-1 ion (m/z 726)
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increased as the increase of the analyte (R)-3 and the intensity of the (S)-3 + (S)-4 ion
(m/z 740) increased as the increase of the analyte (S)-3.
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Figure 2.12: Plots of the complex intensity fraction (CIF) for the selector-analyte
complexes in the ESI-MS versus the mole fraction of (R)-3 in the solution,
using pseudoenantiomeric chiral selectors (S)-4 and (R)-5 (slope = 0.342, r2
= 0.993, α = 2.04); and (S)-1 and (R)-2 (slope = 0.316, r2 = 0.999, α = 1.92).

Plots of the complex intensity fraction (CIF; in this case we use the intensity of
(R)-selector analyte complex divided by the sum of the intensities for both
selector-analyte complexes) versus the mole fraction of the (R)-3 in the solution for 5
different enantiomeric compositions are presented in Figure 2.12. Each plot is linear with
the correlation coefficient of 0.993 (for (S)-4/(R)-5) and 0.999 (for (S)-1/(R)-2)
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respectively. These plots can be used for subsequent enantiomeric assays. Simply
measuring the CIF of the selector-analyte complexes in the mass spectrum and applying
this value to the calibration line affords the enantiomeric composition of the sample.
According to the Equation 1.3, the αMS is calculated to be 2.04 (for selector (S)-4 and
(R)-5) and 1.92 (for selector (S)-1 and (R)-2), respectively.
The enantioselectivity of chiral selector (S)-4 and (R)-5 are also tested by the
analyte 14, which has similar structure to analyte 3. A series of solutions containing 1:1
mixture of selector 4 and 5, and different enantiomeric compositions of analyte 14 were
prepared for ESI-MS. The enantiomeric compositions of analyte 14 determined by HPLC
are as follow: (a) 100% (R)-14, (b) 74.21% (R)-14, (c) 50.24 % (R)-14, (d) 24.17%
(R)-14 and (e) 0% (R)-14. A linear relationship between the CIF and the enantiomeric
compositions of the analyte was also observed in this case. Also, to compare the
enantioselectivity, the ESI-MS of chiral selector 1, 2 and analyte 14 was performed in the
same conditions as the chiral selector 4, 5 and analyte 14 with addition of excess NH4Cl.
The solution and the ESI-MS conditions are all the same as the experiment of analyte 3.
Plots of the CIF versus the mole fraction of the (R)-14 in the solution at 5
different enantiomeric compositions are presented in Figure 2.13. Each plot is linear with
the correlation coefficient of 0.994 (for (S)-4/(R)-5) and 0.992 (for (S)-1/(R)-2). The αMS
is calculated to be 1.48 (for selector (S)-4 and (R)-5) and 1.58 (for selector (S)-1 and
(R)-2) respectively, according to equation 1.3.
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Figure 2.13: Plots of the complex intensity fraction (CIF) for the selector-analyte
complexes in the ESI-MS versus the mole fraction of (R)-14 in the solution,
using pseudoenantiomeric chiral selectors (S)-4 and (R)-5 (slope = 0.195, r2
= 0.994, α = 1.48); and (S)-1 and (R)-2 (slope = 0.226, r2 = 0.992, α = 1.58).

Conclusion
The evaluation of quaternary ammonium salt appended derivatives of
N-(3,5-Dinitrobenzoyl)leucine

as

pseudoenantiomeric

chiral

selectors

for

the

determination of enantiomeric composition by ESI-MS is demonstrated above. Solutions
containing two different quaternary ammonium salt appended derivatives of
N-(3,5-Dinitrobenzoyl)leucine chiral selectors and corresponding analyte afford
positively charged selector-analyte complexes in the electrospray ionization mass
spectrum, and the relative peak intensities can be related back to the enantiomeric
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composition of the analyte. The enantioselectivity using the newly developed quaternary
ammonium salt chiral selectors can be determined by plotting CIF versus XR (α = 2.04
for analyte 3 and α = 1.48 for analyte 14), which is comparable to the enantioselectivity
using the previously designed tertiary amine appended chiral selectors (α = 1.92 for
analyte 3 and α = 1.58 for analyte 14).
In this experiment, we also tried to lower the concentration of chiral selector and
analyte to 1 mM and 0.2 mM respectively. The lower concentration of solution is good
for the maintenance of the MS instrument. The enantioselectivity is still comparable to
the result obtained previously at higher concentration.
The composition of solvent and the conditions of MS (such as capillary voltage,
cone voltage, extractor voltage, desolvation temperature etc) have not been optimized.
The enantioselectivity of these new chiral selectors compared with the previous tertiary
amine appended chiral selector 1 and 2 is not neither obviously improved nor impaired. It
is proved that the use of the quaternary ammonium salt chiral selectors is feasible and
effective to the enantiomer assays without the addition of excess of weak acid or salt.
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CHAPTER III
4-(3,5-DINITROBENZAMIDO)-1,2,3,4-TETRAHYDROPHENANTHRENE
DERIVATIVES AS CHIRAL SELECTORS FOR ENANTIOMER
ASSAYS OF NAPROXEN BY ESI-MS

Introduction
In

this

chapter,

the

use

of

4-(3,5-dinitrobenzamido)-1,2,3,4-tetrahydro-

phenanthrene and its derivatives as chiral selectors for the enantiomeric analysis of
naproxen using ESI-MS is discussed.

COOH

COOH
CH3O
Naproxen (15)

Ibuprofen (16)
O
COOH

Ketoprofen (17)
Figure 3.1: Structures of racemic naproxen, ibuprofen and ketoprofen.
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A variety of 2-arylmethylpropionic acids (profens) have been widely used as
non-steroidal anti-inflammatory drugs (NSAID) for the relief of inflammation, pain, fever,
and stiffness, especially in the treatment of arthritis [67, 68]. Examples are naproxen (15),
ibuprofen (16) and ketoprofen (17) (Figure 3.1). All of these profens are chiral and the
chiralities of these molecules arise from the sp3-α carbon.
(S)-Naproxen tablets were first approved by the U.S. Food and Drug
Administration (FDA) as the prescription drug Naprosyn in 1976 and naproxen sodium
was first marketed under the trade name Anaprox in 1980. In 1991, FDA approved the
use of naproxen sodium as an over-the-counter (OTC) drug. On January 11, 1994, the
FDA approved naproxen in a nonprescription form. Nowadays, (S)-naproxen, used for the
treatment of arthritis, is the fifth largest selling drug in the world -[69, 70].
Considerable effort has been devoted to improving methods for the asymmetric
synthesis and resolution of profens, because their anti-inflammatory and analgesic
pharmaceutical effects are attributed almost exclusively to their S-enantiomers [71]. To
avoid the side effects of the (R)-enantiomer, the use of pure (S)-enantiomer of profens is
desirable. Furthermore, the metabolic and pharmacokinetic studies of both isomers
require enantiomeric pure profens. Hence the analysis of enantiomeric composition of
naproxen as well as other profens has attracted a lot of attention [72].
Chiral separations of profens by HPLC using both indirect and direct methods
have been studied extensively. In the indirect method, diastereomers of analyte profen is
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formed by derivatization and then separated using a chiral column. In the direct method,
the CSPs are used to separate the enantiomers of profen without the derivatization step.
Since the 1980’s, many direct chiral separations of profens on HPLC CPSs have been
reported. Example of the CSPs used for the direct separations of profens is the
derivatized polysaccharide adsorbed on macroporous silica gel such as Chiralcel OD,
Chiralcel OJ, and Chiralpak AD [73-77].

HN
O2N

HN
O 2N

O
Si

O

O

NO2

NO2
Chiral Selector 18

(3S, 4R)-Whelk-O1 CSP

Figure 3.2: Structure of (3S,4R)-Whelk-O-1 CSP and 4-(3,5-dinitrobenzamido)1,2,3,4-tetrahydrophenanthrene (18) selector.

Whelk-O1 CSP is another good example to separate the enantiomers of
arylpropionic acids such as naproxen, which was first reported by Pirkle and coworkers
in

1992

[78,

79]

(Figure

3.2).

In

this

CSP,

4-(3,5-dinitrobenzamido)-

1,2,3,4-tetrahydrophenanthrene (18) was used as the chiral selector (Figure 3.2).
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X

X

X
π

σ*

Figure 3.3: Half-chair conformation of cyclohexenes and overlap of the π-orbital of the
double bond and an antibonding orbital of the allylic σ-bond [81].

Selector 18 has a 3,5-DNB group in the benzylic position of the
tetrahydrophenanthrene moiety. This benzylic substituent may adopt two conformations,
in either a pseudoaxial or a pseudoequatorial position. Lessard et al. [80] reported that the
electronegative groups in an allylic position on cyclohexenes prefer the pseudoaxial
position. This might be attributed to an overlap of a π-orbital of the double bond and an
antibonding orbital of the allylic σ-bond (Figure 3.3). Because the benzylic position in
tetrahydrophenanthrene is similar to the allylic position in cyclohexene, the most stable
conformer for selector 18 may have the 3,5-DNB group in the pseudoaxial position. Due
to the pseudoaxial position of the 3,5-DNB moiety, selector 18 forms a cleft in which the
π-basic naphthyl moiety can be considered as a floor and the π-acidic DNB group can be
considered as a wall. The wall is almost perpendicular to the floor (Figure 3.4) [81].
X-ray crystal structure determination has verified this proposed geometry [82].
54

. . . 3,5-Dinitrobenzoyl group

Cleft

...-----/

.
Amide-rutrogen

•
••

Tetrahydrophenanthrene ring

Figure 3.4: The most stable conformation of selector 18 having the 3,5-DNB group in the
pseudoaxial position (hydrogen atoms are omitted for clarity) [81].

Based on chromatographic structure-activity relationship, crystallographic data
and NMR studies in solution, a chiral recognition model which accounts for the ability of
the Whelk-O1 selector to separate naproxen enantiomers that contains a hydrogen bond
acceptor and an aromatic moiety has been developed [82-87]. The cleft-like structure of
the Whelk-O1 selector appears to be very important to the enantioselectivity. While both
enantiomers of analyte diffuse into the cleft, only one can maintain a heavily populated
low energy conformation [81].
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Column: (RRl-Whelk-O I 25 cm x 4. 6 mm
Mobile Phase: ( 6(1140) Hexane/IPA+
0.1 % Acetic acid

Flow Rate: 1.0 mUmin
Detection: UV 254 nm
Rwi Time 10.5 min
oc 2.03

0

5

10 mm

Figure 3.5: Chromatogram of racemic naproxen on (R,R)-Whelk-O1 column [88].

The enantiomers of naproxen can be separated well on Whelk-O1 CSP, with
chromatographic separation factors of 2.03 [88] (Figure 3.5). In this separation, the
(S)-naproxen is more retained on (S, S)-Whelk-O1 CSP while (R)-naproxen is more
retained on (R,R)-Whelk-O1 CSP. Since the efficient enantioselectivity between
Whelk-O1 CSPs and naproxen, herein, the soluble analogues of Whelk-O1 CSPs, 18, 19
and 20 (Figure 3.6) are synthesized and their utilization as pseudoenantiomers for
enantiomer assays by ESI-MS is discussed in this chapter.
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Figure 3.7: Preparation of chiral selector 18.
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O

C NMR spectra were recorded on a Bruker AMX-300

spectrometer operating at 300 MHz for 1H and 75 MHz for 13C.

before use. 1H NMR and

before use. Tetrahydrofuran (THF) was dried over potassium metal and freshly distilled

further purification. Dichloromethane (CH2Cl2) was dried over CaH2 and freshly distilled

Chemical reagents were obtained from Aldrich Chemical Co. and used without

Experimental

Figure 3.6: Structures of chiral selectors 18-20.
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Preparation of racemic 4-amino-1,2,3,4-tetrahydrophenanthrene, 22 [81]
21 was available from a previous study. A mixture of 1.0 g (5.1 mmol)
4-oxo-1,2,3,4-tetrahydrophenanthrene (21), 5.80 g (75.2 mmol) ammonium acetate, and
2.2 g (35.0 mmol) sodium cyanoborohydride in 60 mL of 2-propanol was heated at reflux
for 24 hours. 1 M aqueous sodium hydroxide solution was added until the solution was
basic. The mixture was extracted with dichloromethane (3 × 30 mL) and the combined
organic layers were washed with saturated ammonium chloride solution (3 × 30 mL),
dried over anhydrous magnesium sulfate, and the solvent was removed by rotary
evaporation under reduced pressure to afford 0.75 g of yellow solid. Flash
chromatography using EtOAc and hexane (1:2) as the mobile phase yielded 0.35 g (1.77
mmol, 35%) of pale yellow oil.
1

H NMR (300 MHz, CDCl3): δ 8.14 (d, J = 8.4 Hz, 1H), 7.79 (d, J = 7.9 Hz, 1H),

7.64 (d, J = 8.3 Hz, 1H), 7.52 (m, 1H), 7.42 (m, 1H), 7.18 (d, J = 8.3 Hz, 1H), 4.69 (m,
1H), 2.91 (m, 2H), 1.70-2.11 (m, 6H). 13C NMR (75 MHz, CDCl3): δ 137.5, 134.0, 132.3,
130.6, 130.0, 128.9, 128.1, 126.6, 126.5, 122.7, 45.4, 30.1, 28.6, 17.8. ESI-MS: 198
[M+H] +.

Preparation of racemic 4-(3,5-dinitrobenzamido)-1,2,3,4-tetrahydrophenanthrene, 18 [63]
To a stirred suspension of 0.35 g (1.77 mmol) of 4-amino-1,2,3,4-tetrahydrophenanthrene, 22, in 15 mL of methylene chloride (dried over CaH2) was added 0.99 mL
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(7.08 mmol) of triethylamine dropwise, followed by 0.61 g (2.66 mmol) of
3,5-dinitrobenzoyl chloride. After stirred at room temperature for 4 hours, the reaction
mixture was diluted with 50 mL of methylene chloride, washed with 2 M HCl (3 × 30
mL), 5% NaHCO3 (3 × 30 mL), water (30 mL once) and dried over anhydrous
magnesium sulfate. The solvent was removed by rotary evaporation under reduced
pressure to afford 0.56 g of brown solid. Flash chromatography using EtOAc and hexane
(15:85) as the mobile phase yielded 0.52 g (1.33 mmol, 75%) of yellow solid, m.p.
243-245 °C.
1

H NMR (300 MHz, CDCl3): δ 9.10 (m, 1H), 8.87 (m, 2H), 7.88 (d, J = 8.1 Hz,

1H), 7.78 (m, 2H), 7.46 (m, 2H), 7.29 (m, 1H), 6.70 (m, 1H), 5.99 (m, 1H), 3.05 (m, 2H),
2.44 (m, 1H), 1.90-2.13 (m, 3H).

13

C NMR (75 MHz, CDCl3): δ 161.4, 148.5, 138.0,

137.8, 136.4, 132.6, 131.9, 128.8, 127.9, 127.2, 127.1, 125.5, 122.4, 121.1, 112.2, 44.9,
29.8, 29.1, 18.1. ESI-MS: 390 [M-H] -.
Racemic selector 18 was resolved by LC on a column packed with
N,N-diallyl-(S)-naproxen derived CSP [89]. The separation conditions were as follows:
mobile phase, 20% THF in hexanes; flow rate, 5.5 mL/min; column dimensions, 30 × 1
in. Injection of 0.50 g of racemic 18 yielded 0.23 g of the (S)-enantiomer (came out first,
>99% ee) followed by 0.22 g of the (R)-enantiomer (>99% ee) in a single pass through
the column. Then a flash column chromatography using EtOAc and hexane (1:5) as the
mobile phase was performed to purify each enantiomer.
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Figure 3.8: Preparation of racemic 19 and 20.

Preparation of 3-(naphthalen-2-yloxy)-propionitrile, 25 [90]
A mixture of 5.48 mL of acrylonitrile (83.2 mmol), 3.0 g of 2-naphthol (20.8
mmol) and 1.36 mL t-Bu4NOH solution (40% wt in water) was heated at reflux for 18
hours. The reaction mixture was extracted with CH2Cl2 (3 × 30 mL). The organic layer
was washed with 2.5% NaOH solution (3 × 30 mL), water (3 × 30 mL), and dried over
anhydrous magnesium sulfate. The solvent was removed by rotary evaporation under
reduced pressure to afford the brown crude product. Flash chromatography using EtOAc
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and hexane (15:85) as the mobile phase yielded 3.20 g (16.2 mmol, 78%) of colorless
crystals, m.p. 105-107 °C.
1

H NMR (300 MHz, CDCl3): δ 7.76 (m, 3H), 7.47 (m, 1H), 7.37, (m, 1H), 7.17

(m, 1H), 7.12 (s, 1H), 4.31 (t, J = 6.4 Hz, 2H), 2.90 (t, J = 6.3 Hz, 2H).

13

C NMR (75

MHz, CDCl3): δ 155.5, 134.1, 129.6, 129.1, 127.5, 126.7, 126.5, 124.0, 118.4, 117.2,
106.8, 62.3, 18.3. ESI-MS: 198 [M+H]+.

Preparation of compound 27 [90]
2.00 g (10.1 mmol) of 25 was added to 20 mL vigorously stirred 85% H2SO4. The
reaction mixture was stirred for 2 hours, and then poured into 30 mL ice-water, and then
allowed to stand overnight. The reaction mixture was extracted with EtOAc (3 × 30 mL).
The organic layer was washed with 5% NaOH solution (3 × 30 mL), water (3 × 30 mL),
and dried over anhydrous magnesium sulfate. The solvent was removed by rotary
evaporation under reduced pressure to afford orange oil. Flash chromatography using
EtOAc and hexane (1:4) as the mobile phase yielded 1.61 g (8.12 mmol, 80%) of yellow
oil.
1

H NMR (300 MHz, CDCl3): δ 9.45 (d, J = 8.4, 1H), 7.91 (d, J = 9.0, 1H), 7.74 (d,

J = 7.9, 1H), 7.63 (m, 1H), 7.42 (m, 1H), 7.09 (d, J = 9.0, 1H), 4.61 (t, J = 6.6 Hz, 2H),
2.91 (t, J = 6.5 Hz, 2H). 13C NMR (75 MHz, CDCl3): δ 192.8, 163.9, 137.4, 131.7, 129.6,
129.2, 128.5, 126.1, 124.9, 118.8, 112.9, 67.1, 38.9. ESI-MS: 199 [M+H]+.
61

Preparation of compound 29 [91]
Hydroxylamine hydrochloride (0.69 g, 10.0 mmol) and sodium acetate (0.82 g,
10.0 mmol) were dissolved in 13 mL of water. A solution of 27 (0.99 g, 5.0 mmol) in of
13 mL methanol was added dropwise to the above aqueous solution. The reaction mixture
was stirred and heated to reflux at 90°C for 24 hours. Aqueous 5% NaHCO3 solution was
added until the pH of the mixture was 7 and it was extracted with CH2Cl2 (5 × 25 mL).
The organic extracts were washed with brine (3 × 30 mL), and dried over anhydrous
magnesium sulfate. The solvent was removed by rotary evaporation under reduced
pressure to afford 1.01 g of yellow solid. Flash chromatography using EtOAc and hexane
(1:4) as the mobile yielded 0.94 g (4.40 mmol, 88%) of yellow oil.
1

H NMR (300 MHz, CDCl3): δ 9.06 (m, 2H), 7.67 (m, 2H), 7.51 (m, 1H), 7.33 (m,

1H), 7.04 (d, J = 8.8, 1H), 4.20 (t, J = 6.3 Hz, 2H), 3.13 (t, J = 6.3 Hz, 2H). 13C NMR (75
MHz, CDCl3): δ 157.0, 152.1, 132.0, 130.7, 129.9, 128.4, 127.7, 126.6, 124.0, 118.7,
111.3, 65.0, 24.9. ESI-MS: 214 [M+H]+.

Preparation of compound 31 [92]
A mixture of 29 (0.63 g, 2.95 mmol), Raney Nickel (2.0 g, Raney® 2800 nickel,
finely divided powder, slurry in water, active catalyst, Ni ≥ 89%) and methanol (60 mL)
was shaken under hydrogen pressure 50 PSIg for 20 hours. The catalyst was filtered off
through celite (Filter agent, Celite® 545). The solvent was removed by rotary evaporation
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under reduced pressure to afford yellow oil. Flash chromatography using EtOAc and
hexane (2:3, then 3:1) as the mobile phase yielded 0.51 g (2.56 mmol, 87%) of yellow
oil.
1

H NMR (300 MHz, CDCl3): δ 7.98 (d, J = 8.3, 1H), 7.72 (d, J = 7.9, 1H), 7.61 (d,

J = 9.1, 1H), 7.48 (m, 1H), 7.30 (m, 1H), 7.02 (d, J = 9.1, 1H), 4.54 (m, 1H), 4.34 (m,
2H), 2.15 (m, 1H), 1.87 (m, 1H), 1.68 (m, 2H).

13

C NMR (75 MHz, CDCl3): δ 151.8,

132.6, 129.1, 129.0, 128.6, 126.7, 123.1, 121.6, 119.0, 116.9, 60.9, 40.5, 30.9. ESI-MS:
200 [M+H]+.

Preparation of selector 19 [63]
19 was prepared using the same procedures as described above, starting from 0.50
g (2.51 mmol) of 31 and 1.39 mL (10.0 mmol) of triethylamine, 0.86 g (3.75 mmol) of
3,5-dinitrobenzoyl chloride in 22 mL CH2Cl2. After flash chromatography using EtOAc
and hexane (1:4) as the mobile phase, 0.77 g (1.96 mmol, 78%) of yellow crystals was
obtained, m.p. > 260 °C.
1

H NMR (300 MHz, CDCl3): δ 9.16 (m, 1H), 8.93 (m, 2H), 7.79 (m, 3H), 7.50 (m,

1H), 7.38 (m, 1H), 7.13 (d, J = 8.9, 1H), 6.73 (m, 1H), 5.84 (m, 1H), 4.53 (m, 1H), 4.27
(m, 1H), 2.44 (m, 2H).

13

C NMR (75 MHz, Acetone-d6): δ 154.4, 149.6, 138.5, 134.0,

131.0, 130.0, 129.4, 128.4, 128.0, 124.3, 122.6, 121.7, 119.9, 112.7, 107.9, 62.7, 41.8,
41.6. ESI-MS: 392 [M-H] -.
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Racemic selector 19 was resolved using the same way as the resolution for
racemic selector 18. Injection of 0.50 g of racemic 19 yielded 0.23 g of the
(S)-enantiomer (came out first, >99% ee) followed by 0.21 g of the (R)-enantiomer
(>99% ee) in a single pass through the column. Then a flash column chromatography
using EtOAc and hexane (1:5) as the mobile phase was performed to purify each
enantiomer.

Preparation of 3-(Naphthalen-2-ylsulfanyl)-propionitrile, 26 [90]
To a stirred, externally cooled mixture of t-Bu4NOH solution (1.36 mL, 40% wt in
water) and acrylonitrile (5.48 mL, 83.2 mmol), 3.33 g 2-naphthiol (20.8 mmol) was
added in small portions during twenty minutes. The reaction mixture was then kept at
65°C for one hour. The mixture was diluted with 50 mL ethyl ether, and 0.5 mL of acetic
acid was added to neutralize the catalyst. The mixture was extracted with CH2Cl2 (3 × 30
mL). The organic layer was washed with 2.5% NaOH solution (3 × 30 mL), water (3 × 30
mL), and dried over anhydrous magnesium sulfate. The solvent was removed by rotary
evaporation under reduced pressure to afford 5.13 g of brown solid. The crude product
was used without further purification.
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Preparation of compound 28 [90]
28 was prepared using the same procedures as described above, starting from 2.0
g (9.38 mmol) of 4. 0.92 g of brown oil was obtained. Flash chromatography using
EtOAc and hexane (1:9) as the mobile phase yielded 0.69 g (3.22 mmol, 34%) of yellow
solid, m.p. 67-69 °C.
1

H NMR (300 MHz, CDCl3): δ 9.15 (d, J = 8.6, 1H), 7.72 (m, 2H), 7.58 (m, 1H),

7.42 (m, 1H), 7.24 (d, J = 8.7, 1H), 3.25 (m, 2H), 3.08 (m, 2H).

13

C NMR (75 MHz,

CDCl3): δ 195.3, 144.6, 132.9, 131.9, 131.1, 128.5, 127.9, 125.6, 125.0, 124.9, 124.8,
40.6, 25.7. ESI-MS: 215 [M+H]+.

Preparation of selector 20 [91]
30 was prepared using the same procedures as described above, starting from 1.07
g (5.0 mmol) of 28. 1.03 g (4.49 mmol, 90%) of yellow solid was obtained. The crude
oxime was used without further purification. 32 was prepared from 0.68 g (2.95 mmol) of
30, following the same procedure as the preparation of 31. 0.56 g (2.60 mmol, 88%) of
yellow oil was obtained. The crude amine was used without further purification. 20 was
prepared from 0.38 g (1.77 mmol) of 32, following the same procedure as the preparation
of 18. 0.39 g (0.95 mmol, 54%) of yellow solid was obtained, m.p. 253-255 °C.
1

H NMR (300 MHz, CDCl3): δ 9.17 (m, 2H), 9.11 (m, 1H), 8.65 (m, 1H), 7.87 (d,

J = 8.5, 1H), 7.75 (d, J = 7.7, 1H), 7.65 (d, J = 8.7, 1H), 7.48 (m, 1H), 7.39 (m, 1H), 7.16
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(d, J = 8.9, 1H), 6.14 (m, 1H), 3.40 (t, J = 13.0, 1H), 2.75-3.00 (m, 2H), 2.17-2.29 (m,
1H). 13C NMR (75 MHz, Acetone-d6): δ 159.4, 148.3, 137.4, 134.8, 132.3, 130.5, 129.7,
128.6, 128.1, 125.3, 124.6, 123.2, 122.8, 120.7, 117.9, 42.9, 42.3, 32.0. ESI-MS: 408
[M-H] -.
Racemic selector 20 was resolved using the same way as the resolution for
racemic selector 18. Injection of 0.40 g of racemic 20 yielded 0.17 g of the
(S)-enantiomer (came out first, >99% ee) followed by 0.16 g of the (R)-enantiomer
(>99% ee) in a single pass through the column. Then a flash column chromatography
using EtOAc and hexane (1:5) as the mobile phase was performed to purify each
enantiomer.

Preparation of solutions
Stock solutions of (R)-15 (90% R), (Racemic)-15, and (S)-15 were prepared in
methanol at the concentration of 2 mM. The enantiomeric composition of each stock
solution was determined by HPLC (see below for HPLC conditions). 1:1 mole of (S)-18
and (R)-19 were mixed and dissolved in THF to afford the stock solution of
pseudoenantiomeric selectors at the concentration of 5 mM; the stock solution of selector
pair (S)-20, (R)-19 and (S)-18, (R)-20 was prepared in the same way. The final solutions
were made by combining the calculated amount of the corresponding stock solutions of
analyte and pseudoenantiomeric selectors, and diluting with methanol, water and THF.
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The final concentration for each solution is 0.33 mM for each chiral selector and 0.067
mM for analyte in water/methanol/THF (4:4:7).

Determination of enantiomeric composition of stock solutions of analyte 15 by HPLC
High performance liquid chromatography (HPLC) was performed using the
system consisted of a Beckman System Gold Programmable Solvent Module 125 HPLC
pump, a Rheodyne 7725i injector with a 20-µL sample loop, a HP Hewlett Packard series
1050 UV detector operating at 254 nm and an SRI model 302 PeakSimple
Chromatography Data System six-channel recorder.
Analytical chromatography was carried out with a commercial version of
(R,R)-Whelk-O1 chiral column (4.6 × 250 mm, available from Regis Technologies). All
solvents used were HPLC grade and used without further purification.
20 µL of each stock solution of analyte was injected into HPLC system. HPLC
conditions were as follows: mobile phase, hexane/2-propanol (70:30) + 0.01 M
ammonium acetate; flow rate, 2 mL/min; column dimensions, 4.6 × 250 mm. The peak
was monitored with UV-detector at λ = 254 nm. Each solution was measured three times,
and the average value of these three tests was used as the enantiomeric composition of
analyte in the final solutions. The void time was determined by recording the retention
time of 1,3,5-tri-tert-butylbenzene at the same condition.
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Mass spectrometry
All mass spectra were obtained on a Micromass Quattro Micro (Beverly, MA)
triple quadrupole mass spectrometer with electrospray ionization running in the negative
ion mode. Solutions were infused with a syringe pump into the ESI source at a rate of 20
µL/min. Spectrometer conditions were as follows: capillary voltage, 1.0 kV; Cone voltage,
10.0 V; extractor voltage, 1.0 V; RF lens, 0.5 V; source temperature, 80°C; desolvation
temperature, 300°C; cone gas flow, 71 L/h; desolvation gas flow, 609 L/h. For each
sample of direct infusion, a full scan required about 1 s. The data collected over a 1-min
period were averaged to afford the final spectrum.

Results and Discussion
Chiral selectors 18, 19 and 20 were prepared and used as pseudoenantiomers to
mimic the interaction between the selector and analyte in liquid chromatography. The
selector and analyte were considered to form a pair of diastereomeric complexes in liquid
phase. As mentioned above, a chiral recognition model which accounted for the ability of
the Whelk-O1 selector to differentiate between enantiomers of naproxen could be
established as shown in Figure 3.9. In this model, the electron-deficient
3,5-dinitrobenzoyl group and the electron-rich tetrahydrophenanthrene ring participate in
face-to-face and face-to-edge interactions, respectively with the aryl group of naproxen.
Furthermore, the amide proton participates in hydrogen bonding. The cleft-like structure
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of the Whelk-O1 selector appears to be important to enantioselectivity. Only one
enantiomer of a given racemic analyte can diffuse into the cleft, undergoing all three of
the aforementioned interactions simultaneously while maintaining a heavily populated
low energy conformation [81].
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Figure 3.9: A chiral recognition model which accounts for the ability of the Whelk-O1
selector to differentiate between enantiomers of naproxen [81].

The chiral selectors of 19 and 20 were synthesized by replacing a CH2 group in
the tetrahydrophenanthrene of 18 with a heteroatom (O, S) respectively. Due to the
similarity of the newly designed chiral selectors 19 and 20 to the structure of 18, the
ability of forming diastereomeric complexes and the chiral recognition in solution should
maintain.
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In this study, the solutions containing the pseudoenantiomeric selectors and
naproxen were performed in the negative ion mode of ESI-MS. That is because the
carboxylic acid group of naproxen allows ready deprotonation and detection of the
complex between the analyte and selector in the negative ion mode of ESI. In addition,
negative mode ionization avoids the additional complication of having other positive ions
like H+, Li+, or Na+ present in the solution which likely interferes with the requisite
selector-analyte hydrogen bonds needed for effective chiral recognition.

NO2
O 2N

HN

(S)-18

COOH
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NO2
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O
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Figure 3.10: ESI-MS of solutions containing pseudoenantiomeric chiral selectors (S)-18,
(R)-19 and analyte 15.
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First, the mass spectrometric experiment was performed using (S)-18 and (R)-19
as pseudoenantiomeric chiral selectors. A solution containing 1:1 mixture of (S)-18 and
(R)-19 was prepared as the stock solution. The final solution was made to contain 0.33
mM in both (S)-18 and (R)-19, and 0.067 mM in analyte 15. The enantiomeric
composition of 15 in each solution was varied, which was determined by HPLC. In each
case the solvent was a mixture of methanol, water and THF (4:4:7). Negative ion mode
electrospray ionization was performed on the solutions of chiral selector (S)-18 and
(R)-19, and analyte 15 (Figure 3.10). The anions of selector-analyte complexes were
observed in the mass spectrometry. This spectrum was obtained by infusing the sample
into the spectrometer at a flow rate of 20 µL/min with a syringe pump. The mass
spectrum is extracted by averaging about 1 min of the total ion count (TIC).

71

Scan ES-

392

100

%

[19 - H]-

[15 + 18 - H]-

[18 - H]-

[15 + 19 - H]-

[15 - H]-

229

390
[152 + Na - H]

0

\482

-

620

[18 + 19 - H]-

622

[192 - H]-

[182 - H]- 783785

------781{

200 250 300 350 400 450 500 550 600 650 700 750 800 850 900 950 1000
m/z

Figure 3.11: Mass spectrum of a solution of pseudoenantiomeric selectors (S)-18 and
(R)-19 (0.33 mM for each) and racemic analyte 15 (0.067 mM) in
water/methanol/THF (4:4:7).

Figure 3.11 shows the full mass spectrum for the solution containing racemic
analyte 15 and chiral selector (S)-18 and (R)-19. The monomeric anions of analyte [15 H]- and chiral selectors, [18 - H]- and [19 - H]-, are observed at m/z 229, 390, and 392,
respectively. The dimeric anions of selectors are observed at m/z 781 [182 - H]-, 783 [18 +
19 - H]- and 785 [192 - H]-. The dimeric anion of analyte is observed at m/z 482 [152 + Na
- H]-. The analyte-selector hetero-dimers, [15 + 18 - H]- and [15 + 19 - H]-, are observed
at m/z 620 and 622 respectively.
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Figure 3.12: Partial electrospray ionization mass spectrum of pseudoenantiomeric chiral
selectors (S)-18 and (R)-19 (0.33 mM for each), analyte 15 (0.067 mM) in
water/methanol/THF (4:4:7). The enantiomeric compositions of analyte 15
are as follow: (a) 90.03% (R)-15, (b) 49.23% (R)-15 and (c) 0% (R)-15.

Partial mass spectra of pseudoenantiomeric selectors (S)-18 and (R)-19, and
analyte 15 are shown in Figure 3.12. The enantiomeric compositions of analyte 15 in the
three solutions are as follow: (a) 90.03% (R)-15, (b) 49.23% (R)-15 and (c) 0% (R)-15.
The relative intensities of the selector-analyte complexes vary regularly with the
enantiomeric composition of the analyte, clearly demonstrating chiral recognition. As the
amount of (R)-15 is increased in the sample, the complex with the (R)-19 selector is
increased relative to the complex with the (S)-18 selector (m/z 622 vs m/z 620); likewise,
73

as the amount of (S)-15 is increased in the sample, the complex with the (S)-18 selector is
increased relative to the complex with the (R)-19 selector.
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Figure 3.13: Mass spectrum of a solution of pseudoenantiomeric selectors (S)-20 and
(R)-19 (0.33 mM) and racemic analyte 15 (0.067 mM) in
water/methanol/THF (4:4:7).

In the same manner, the compound 19 and 20 were tested as the
pseudoenantiomeric chiral selectors. Figure 3.13 shows the full negative ion mass
spectrum for the solution containing racemic analyte 15 and chiral selector (S)-20 and
(R)-19. The analyte-selector hetero-dimers, [15 + 19 - H]- and [15 + 20 - H]-, are
observed at m/z 622 and 638 respectively.
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Figure 3.14: Partial electrospray ionization mass spectrum of pseudoenantiomeric chiral
selectors (S)-20 and (R)-19 (0.33 mM for each), analyte 15 (0.067 mM) in
water/methanol/THF (4:4:7). The enantiomeric compositions of analyte 15
are as follow: (a) 90.03% (R)-15, (b) 49.23% (R)-15 and (c) 0% (R)-15.

Figure 3.14 shows the partial mass spectra containing the complexes between
selectors (S)-20 and (R)-19, and analyte 15. When the sample is enriched in the
(R)-analyte 15, the relative intensity of the complex between selector (R)-19 and analyte
15 (m/z 622) is increased with respect to the complex between selector (S)-20 and analyte
15 (m/z 638), while the sample is enriched with the (S)-analyte 15, the relative intensity
of the complex between selector (S)-20 and analyte 15 (m/z 638) is increased with respect
to the complex between selector (R)-19 and analyte 15 (m/z 622).
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Figure 3.15: Mass spectrum of a solution of pseudoenantiomeric selectors (S)-18 and
(R)-20 (0.33 mM for each) and racemic analyte 15 (0.067 mM) in
water/methanol/THF (4:4:7).

Additionally, a mixture of the (S)-18 and (R)-20, the third pairwise combination of
the three pseudoenantiomeric selectors (18, 19, and 20), was tested. Figure 3.15 shows
the full negative ion mass spectrum for the solution containing racemic analyte 15 and
chiral selector (S)-18 and (R)-20. The relevant portion of the mass spectrum containing
the selector-analyte complex is shown in Figure 3.16. As in the previous cases, when the
amount of (R)-analyte is increased in the sample, the relative intensity of the complex
between selector (R)-20 and analyte 15 (m/z 638) increases with respect to the complex
between selector (S)-18 and analyte 15 (m/z 620). Likewise, when the amount of
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(S)-analyte is increased in the sample, the relative intensity of the complex between
selector (S)-18 and analyte 15 (m/z 620) increases with respect to the complex between
selector (R)-20 and analyte 15 (m/z 638).
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Figure 3.16: Partial electrospray ionization mass spectrum of pseudoenantiomeric chiral
selectors (S)-18 and (R)-20 (0.33 mM each), analyte 15 (0.067 mM) in
water/methanol/THF (4:4:7). The enantiomeric compositions of analyte 15
are as follow: (a) 90.03% (R)-15, (b) 49.23% (R)-15 and (c) 0% (R)-15.

In each case, it is clear that chiral recognition between the chiral selector 18, 19,
20 and analyte 15 is being observed in the negative ion mode ESI-MS. As the amount of
the (R)-analyte is increased in the sample, the relative intensity of the complex between
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(R)-selector and (R)-analyte is increased. Likewise, the increase in amount of (S)-analyte
gives an increase in the peak intensity of complex between (S)-selector and (S)-analyte.
This is consistent with the observed elution order of naproxen in liquid chromatography
using Whelk-O1 column: the homo selector-analyte complex (i.e., (S)-selector +
(S)-analyte, or (R)-selector + (R)-analyte) is more stable.

I M+2
IM

=

(1.1x)2
+ 0.2w
200

%

Equation 3.1

For each set of data, a plot of the complex intensity fraction (CIF) versus the mole
fraction of the (R)-15 in the solution for 3 different enantiomeric compositions is obtained
(Figure 3.17). The CIF for the pair (S)-20/(R)-19 and pair (S)-18/(R)-20 is calculated as
before. But the calculation needed to be modified for the pair of (S)-18/(R)-19, because
the two peaks of selector-analyte complexes (m/z 620 vs 622) are to close to each other,
the influence of the isotopic peaks of peak 620 can not be ignored. Assume CxHyNzOw as
the molecular formula, the simplified equation (neglect isotopes of low abundance) for
calculating the isotopic distribution of peak [M + 2]- is shown in Equation 3.1 [93, 94].
The peak 620 represents the anion of selector-analyte complex, [15 + 18 - H]-, so
C35H30N3O8 (which is derived from the combination of analyte 15 and selector 18, minus
one hydrogen atom) can be considered as the molecular formula. According to Equation
3.1, using x = 35 and w = 8, the intensity of [M + 2]- peak is 9.01% relative to the
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intensity of [M]- peak (m/z 620). When CIF is calculated, the isotopic distribution of peak
620 will be deducted from the intensity of peak 622.
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Figure 3.17: Plots of the complex intensity fraction (CIF) for the selector-analyte
complexes in the ESI-MS versus the mole fraction of (R)-15 in the solution,
using pseudoenantiomeric chiral selectors (S)-18/(R)-19 (slope = 0.145, r2 =
0.993, α = 1.34); (S)-20/(R)-19 (slope = 0.189, r2 = 0.990, α = 1.47); and
(S)-18/(R)-20 (slope = 0.100, r2 = 0.996, α = 1.22).

Each plot is linear with the correlation coefficient of 0.993 (for (S)-18/(R)-19),
0.990 (for (S)-20/(R)-19) and 0.996 (for (S)-18/(R)-20) respectively. These plots with
linear relationship provide a simple method for determining the enantiomeric
composition of the analyte. Simply measuring the CIF of the selector-analyte complexes
in the mass spectrum with constant conditions and applying this value to the calibration
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line affords the enantiomeric composition of the analyte. According to the Equation 1.3,
the αMS is calculated to be 1.34 (for (S)-18/(R)-19), 1.47 (for (S)-20/(R)-19) and 1.22 (for
(S)-18/(R)-20) respectively. The pair of oxygen derivative (S)-20 and sulfur derivative
(R)-19 gives the best enantioselectivity with αMS = 1.47.

Conclusion
The evaluation of chiral selectors 18, 19 and 20 as pseudoenantiomers for the
determination of enantiomeric composition of naproxen by ESI-MS is demonstrated
above. These chiral selectors used in this study were derived from the well-established
chiral stationary phase Whelk-O1. Solutions containing a pair of pseudoenantiomeric
chiral selectors and analyte afford deprotonated selector-analyte complexes in the
negative ion mode electrospray ionization mass spectrum, and the relative peak
intensities of the complexes can be related back to the enantiomeric composition of the
analyte. In each case of this study, the complex intensity fraction for either of the
selector-analyte complexes in the ESI-MS varies linearly with the enantiomeric
composition of the analyte. This linear relationship provides a measure of the extent of
enantioselectivity and allows quantitative analysis of the enantiomeric composition of
analyte. Additionally, the sense of the observed chiral recognition using the new
developed selectors by ESI-MS is in agreement with the sense of chiral recognition
observed chromatographically using the corresponding Pirkle type CSPs in HPLC.
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CHAPTER IV
N-(3,5-DINITROBENZOYL)-α-AMINO PHOSPHONATE ESTER DERIVATIVES AS
CHIRAL SELECTORS FOR ENANTIOMER ASSAYS OF PROPRANOLOL BY
ESI-MS

Introduction
In this chapter, the use of N-(3,5-dinitrobenzoyl)-α-amino phosphonate ester
derivatives as chiral selectors for the enantiomeric analysis of propranolol using ESI-MS
is discussed.
Propranolol is one of the cardioselective β-adrenoreceptor blocking agents that
block adrenergic stimuli, and are responsible for the stimulation of heart and inhibition of
several

types

of

smooth

muscles

[95].

Chemically,

they

have

the

hydroxylamine-containing structures in which amino groups are always secondary and
they also contain at least one aromatic ring. Propranolol, as well as metoprolol, pindolol
and bufuraolol etc. are typical types of these so-called β-blockers (Figure 4.1). They are
used in the treatment of angina pectoris and hypertension and are also known to reduce
the intensity of migraine headache [95].
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Figure 4.1: Structures of β-blockers.

Owing to their importance, many β-blockers have been developed and a number
are now marketed. Most of β-blockers are chiral compounds and their enantiomers may
have different pharmacological and toxicological effects [96]. Typically, the
S-enantiomers are 50-500 fold more active than their R-enantiomers [97]. Required by
FDA, each enantiomer of the drug should be tested separately for its pharmacological and
metabolic pathways. Moreover, the study of how β-blockers stereochemistry influences
the extent and mode of their pharmacological action requires the enantiomeric pure
sample. Consequently, the chiral analysis of β-blockers is of considerable current interest.
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There are some possible approaches to enantiomeric resolution by use of HPLC.
The enantiomers of β-blockers can be derivatized with a chiral reagent and separation of
the resulting diastereomers by conventional achiral chromatography. The enantiomer
separations on a column containing chiral stationary phases after derivatization with an
achiral reagent have been reported [98, 99]. In some instances, separation can be
completed through the addition of chiral additives to the mobile phase and the use of an
achiral stationary phase [100, 101]. However, the direct separation of underivatized
enantiomers on a CSP has so far proven to be the most useful and convenient method for
determination of enantiomeric purity.
Since the success of Pirkle-type CSPs to the resolution of various racemic
compounds containing π-acidic and/or π-basic functional groups [102-105], a Pirkle-type
CSP 39 (Figure 4.2) which was derived from N-(3,5-dinitrobenzoyl)amino acid was
designed to directly separate the enantiomers of β-blockers without chemical
derivatization [106].

83

O
O2N

H COOH
S

Si

N
HH3C CH3

O

NO2
N-(3,5-dinitrobenzoyl)amino acid CSP 39
O
O
O2N

S

Si

H

O

N P (OCH )
3 2
H O
NO2

Phosphonate ester CSP 40
O

O2N

S

H

Si

O

N P (OCH )
3 2
H O
NO2

Phosphonate ester CSP 41

Figure 4.2: Structures of chiral stationary phases for enantioseparation of propranolol.

By using a mobile phase containing ammonium acetate, the basicity of secondary
amine in β-blockers would be reduced through protonation to form ammonium ion, and
also the carboxylic acid group of the CSP 39 would be converted to a carboxylate group.
Consequently, the ammonium ion portion of the protonated β-blockers could interact
ionically with the carboxylate group of the CSP, which could be considered as one of the
interactions for chiral recognition. However, this ionic interaction is so strong that a
strong eluent has to be used in order to keep retention at a reasonable level. The strong
eluent interferes with the other weaker but essential interactions for chiral recognition. To
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remedy this, Pirkle and coworkers [106, 107] developed the phosphonate ester CSPs 40
and 41 (Figure 4.2), abandoning the use of a formal ionic interaction.
In the case of phosphonate ester CSPs 40 and 41, the interactions between the
chiral selector and β-blocker analyte include: (a) the π-π interaction between the π-acidic
DNB group of the selector and the π-basic aromatic group of the analyte, (b) the
hydrogen bond between the phosphinyl oxygen of the selector and the amine (or
ammonium ion) portion of the analyte and (c) another hydrogen bond between the
dinitrobenzamide proton of the selector and the hydroxyl group of the analyte. Reported
by Pirkle, both CSPs 40 and 41, if of the R configuration, should retain the S enantiomer
of a β-blocker [106].
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Figure 4.3: Chromatogram of enantioseparation of racemic propranolol (35) using
(R)-CSP 40. Conditions are as follow: injected volume, 20 µL; mobile phase,
chloroform/ethanol (95/5) with ammonium acetate 0.5 g/L (6.5 mM); flow
rate, 2 mL/min; temperature, 21°C; detection wave-length, 254 nm. α = 1.39
[106].
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These phosphonate ester CSPs have been reported to be effective in resolving the
enantiomers of racemic β-blockers, such as pindolol, bufuralol and propranolol etc.
Figure 4.3 shows the enantioseparation of racemic propranolol using (R)-CSP 40. The
first peak is R-propranolol, followed by the second peak S-propranolol [106], which is
consistent with the prediction by the chiral recognition model mentioned above (i.e., the
CSPs 40 and 41, if of the R configuration, should retain the S enantiomer of a β-blocker).
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Figure 4.4: Structures of chiral selectors 42-44.

The enantiomers of propranolol can be separated well on phosphonate ester CSPs
40 and 41. It is expected that if the diastereomeric complexes between the soluble
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analogues of these phosphonate ester CSPs could be maintained in gas phase (i.e., could
be maintained in ESI-MS), the chiral recognition will be observed using ESI-MS. Herein,
the chiral selectors 42-44 (Figure 4.4) which are derived from CSPs 40 and 41 will be
synthesized and their utilization as pseudoenantiomers for enantiomer assays of
propranolol by ESI-MS will be discussed in this chapter.

Experimental
Chemical reagents were obtained from Aldrich Chemical Co. and used without
further purification. Dichloromethane (CH2Cl2) was dried over CaH2 and freshly distilled
before use. Tetrahydrofuran (THF) was dried over potassium metal and freshly distilled
before use. 1H NMR and

13

C NMR spectra were recorded on a Bruker AMX-300

spectrometer operating at 300 MHz for 1H and 75 MHz for 13C.
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Figure 4.5: Preparation of racemic chiral selectors 42-44.

Preparation of compound 45 [108]
Benzaldehyde (0.81 mL, 8.0 mmol) was added dropwise during a period of 15
min to a stirred mixture of benzyl carbamate (1.20 g, 7.9 mmol), the dimethyl phosphate
(0.74 mL, 8.1 mmol) and acetyl chloride (AcCl, 6 mL) at -5°C in an ice/salt bath. Stirring
was continued at 0°C for 1 hour. The cooling bath was then removed and the mixture was
stirred at room temperature for 16 hours. The volatile component was removed by rotary
evaporation under reduced pressure. The crude product was recrystallized from
acetone/hexane to afford 2.49 g (7.1 mmol, 90%) of white solid, m.p. 110-112 °C.
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1

H NMR (300 MHz, CDCl3): δ 7.27-7.47 (m, 10H), 5.95 (m, 1H), 5.03-5.27 (m,

3H), 3.73 (d, J = 10.5 Hz, 3H), 3.48 (d, J = 10.5 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ
155.7, 136.0, 134.8, 128.7, 128.4, 128.2, 128.1, 128.0, 127.8, 67.3, 53.7, 52.0 (d, J =
156.4 Hz). ESI-MS: 350 [M+H]+.

Preparation of compound 48 [108]
45 (1.68 g, 4.8 mmol) was dissolved in 50 mL of ethanol, followed by the
addition of 0.30 g of Pd/C catalyst (10 wt. % Palladium on activated carbon). The
reaction mixture was stirred under a hydrogen atmosphere for 24 hours. The catalyst was
filtered off through celite (Filter agent, Celite® 545). The solvent was removed by rotary
evaporation under reduced pressure to afford 1.01 g (4.7 mmol, 98%) of white solid,
ESI-MS: 216 [M+H]+. The crude product was used without further purification.

Preparation of compound 42 [63]
Propylene oxide (1.0 mL, 14.4 mmol) was added via syringe to a mixture of 48
(1.03 g, 4.8 mmol) and 3,5-dinitrobenzoyl chloride (1.22 g, 5.3 mmol) in 50 mL of
freshly distilled tetrahydrofuran in an oven-dried round bottom flask. The mixture was
stirred at room temperature for 24 hours under a nitrogen atmosphere, and then filtered.
The solvent of the filtrate was removed by rotary evaporation under reduced pressure to
afford 1.58 g of white solid. The crude product was purified by flash chromatography
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using EtOAc and hexane (1:1) as the mobile phase. 1.52 g (3.7 mmol, 77%) of white
solid was obtained, m.p. 172-174 °C.
1

H NMR (300 MHz, CDCl3): δ 9.70 (m, 1H), 9.15 (m, 2H), 9.07 (m, 1H), 7.64 (m,

2H), 7.26 (m, 3H), 5.97 (dd, J = 9.5 Hz, 21.1 Hz, 1H), 3.87 (d, J = 11.0 Hz, 3H), 3.51 (d,
J = 10.3 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ 162.9, 148.3, 137.2, 133.9, 128.7, 128.5,
128.4, 128.3, 120.9, 54.1, 50.2 (d, J = 156.1 Hz). ESI-MS: 410 [M+H]+.
Racemic selector 42 was resolved by LC on a column packed with
(L)-NIN-Leucine derived CSP. The separation conditions were as follows: mobile phase,
30% THF in hexanes; flow rate, 5.5 mL/min; column dimensions, 30 × 1 in. Injection of
0.40 g of racemic 42 yielded 0.21 g of the (S)-enantiomer (came out first, 29%
enantiomeric excess) followed by 0.16 g of the (R)-enantiomer (>99% enantiomeric
excess) in a single pass through the column. A flash column chromatography using
EtOAc and hexane (1:1) as the mobile phase was performed to purify the (R)-enantiomer.

Preparation of compound 46 [108]
46 was prepared using the same procedures as described above starting from 0.95
mL (8.0 mmol) of p-tolualdehyde. The crude product was recrystallized from
acetone/hexane to afford 2.52 g (6.9 mmol, 87%) of white solid, m.p. 111-113 °C.
1

H NMR (300 MHz, CDCl3): δ 7.13-7.45 (m, 10H), 5.86 (m, 1H), 5.03-5.22 (m,

2H), 3.74 (d, J = 10.6 Hz, 3H), 3.50 (d, J = 10.3 Hz, 3H), 2.34(s, 3H). 13C NMR (75 MHz,
90

CDCl3): δ 155.6, 137.8, 136.0, 131.8, 129.2, 128.2, 127.9, 127.8, 126.4, 67.0, 53.5, 51.7
(d, J = 156.2 Hz), 20.9. ESI-MS: 364 [M+H]+.

Preparation of compound 49 [108]
49 was prepared using the same procedures as described above starting from 2.48
g (6.8 mmol) of 46, 0.40 g of Pd/C catalyst (10 wt. % Palladium on activated carbon) and
50 mL of ethanol. 1.48 g (6.5 mmol, 96%) of white solid was obtained, ESI-MS: 230
[M+H]+. The crude product was used without further purification.

Preparation of compound 43 [63]
43 was prepared using the same procedures as described above starting from 1.44
g (6.3 mmol) of 49, 1.59 g (6.9 mmol) of 3,5-dinitrobenzoyl chloride and 1.32 mL (18.8
mmol) of propylene oxide. 3.12 g of yellow solid as crude product was obtained. Flash
chromatography using EtOAc and hexane (1:1) as the mobile phase yielded 2.11 g (5.0
mmol, 79%) of white solid, m.p. 154-155 °C.
1

H NMR (300 MHz, CDCl3): δ 9.72 (m, 1H), 9.22 (m, 2H), 9.09 (m, 1H), 7.60 (d,

J = 7.0 Hz, 2H), 7.11 (d, J = 7.8 Hz, 2H), 5.91 (dd, J = 9.5 Hz, 20.7 Hz, 1H), 3.72 (d, J =
10.9 Hz, 3H), 3.55 (d, J = 10.6 Hz, 3H), 2.37 (s, 3H).

13

C NMR (75 MHz, CDCl3): δ

162.9, 148.3, 138.2, 137.4, 130.9, 129.5, 128.6, 128.4, 120.9, 54.2, 49.8 (d, J = 156.3 Hz),
21.1. ESI-MS: 424 [M+H]+.
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Racemic selector 43 was resolved using the same method as for the resolution for
racemic selector 42. Injection of 0.50 g of racemic 43 yielded 0.23 g of the
(S)-enantiomer (came out first, 90% enantiomeric excess) followed by 0.22 g of the
(R)-enantiomer (>99% enantiomeric excess) in a single pass through the column. The
(S)-enantiomer was purified by recrystallization from THF/hexane to afford 0.19 g of
(S)-enantiomer (>99% enantiomeric excess). A flash column chromatography using
EtOAc and hexane (1:1) as the mobile phase was performed to purify the (R)-enantiomer.

Preparation of compound 47 [108]
47 was prepared using the same procedures as described above starting from 0.98
mL (8.1 mmol) of p-anisaldehyde. The crude product was recrystallized from
acetone/hexane to afford 2.68 g (7.1 mmol, 90%) of white solid, m.p. 115-117 °C.
1

H NMR (300 MHz, CDCl3): δ 7.23-7.41 (m, 8H), 6.88 (d, J = 8.3 Hz, 2H), 6.27

(m, 1H), 5.09 (m, 2H), 3.79 (s, 3H), 3.71 (d, J = 11.0 Hz, 3H), 3.46 (d, J = 10.6 Hz, 3H).
13

C NMR (75 MHz, CDCl3): δ 159.5, 155.7, 136.1, 129.1, 129.0, 128.4, 128.1, 126.8,

114.1, 67.2, 55.2, 53.6, 51.4 (d, J = 156.4 Hz). ESI-MS: 380 [M+H]+.
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Preparation of compound 50 [108]
50 was prepared using the same procedures as described above starting from 1.61
g (4.2 mmol) of 47. 1.0 g (4.1 mmol, 98%) of white solid was obtained, ESI-MS: 246
[M+H]+. The crude product was used without further purification.

Preparation of compound 44 [63]
44 was prepared using the same procedures as described above starting from 1.35
g (5.5 mmol) of 50, 1.40 g (6.1 mmol) of 3,5-dinitrobenzoyl chloride and 1.16 mL (16.5
mmol) of propylene oxide. 2.63 g of yellow solid as crude product was obtained. Flash
chromatography using EtOAc and hexane (1:1) as the mobile phase yielded 1.71 g (3.9
mmol, 71%) of white solid, m.p. 171-173 °C.
1

H NMR (300 MHz, CDCl3): δ 9.80 (m, 1H), 9.15 (m, 2H), 9.04 (m, 1H), 7.54 (d,

J = 7.3 Hz, 2H), 6.72 (d, J = 7.9 Hz, 2H), 5.94 (dd, J = 9.4 Hz, 21.0 Hz, 1H), 3.89 (d, J =
10.5 Hz, 3H), 3.73 (s, 3H), 3.56 (d, J = 10.5 Hz, 3H).

13

C NMR (75 MHz, CDCl3): δ

162.8, 159.5, 148.2, 137.2, 129.6, 128.2, 125.8, 120.8, 113.9, 55.1, 54.1, 49.5 (d, J =
156.3 Hz). ESI-MS: 440 [M+H]+.
Racemic selector 44 was resolved using the same way as for the resolution for
racemic selector 42. Injection of 0.50 g of racemic 44 yielded 0.24 g of the
(S)-enantiomer (came out first, 22% enantiomeric excess) followed by 0.21 g of the
(R)-enantiomer (>99% enantiomeric excess) in a single pass through the column. A flash
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column chromatography using EtOAc and hexane (1:1) as the mobile phase was
performed to purify the (R)-enantiomer.

Preparation of solutions
Both enantiomers of propranolol 35 were bought as hydrochloride salt (1
equivalent). The hydrochloride part could be removed by running a short AlO flash
column chromatography using methanol as the mobile phase.
Stock solutions of (R)-35 HCl salt, (Racemic)-35 HCl salt, and (S)-35 HCl salt
were prepared in methanol at the concentration of 2 mM. Also, stock solutions of (R)-35,
(Racemic)-35, and (S)-35 were prepared in methanol at the concentration of 2 mM. The
enantiomeric composition of each stock solution was determined by HPLC (see below for
HPLC conditions). 1:1 mole of (R)-42 and (S)-43 were mixed and dissolved in methanol
to afford the stock solution of pseudoenantiomeric selectors at the concentration of 5 mM.
The stock solution containing selectors (R)-44 and (S)-43 was prepared in the same way.
The stock solution of ammonium chloride was prepared in water at the concentration of 2
mM. The stock solutions of acetic acid and formic acid were prepared in the same way,
respectively. The final solutions were made by combining the calculated amount of the
corresponding stock solutions of analyte, pseudoenantiomeric selectors and additives and
diluting with water. The final concentration for each solution is 1.0 mM for each chiral
selector, 0.2 mM for analyte and 0.2 mM for additive in water/methanol (1:1).
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Determination of enantiomeric composition of stock solutions of analyte 35 by HPLC
High performance liquid chromatography (HPLC) was performed using the
system consisted of a Beckman System Gold Programmable Solvent Module 125 HPLC
pump, a Rheodyne 7725i injector with a 20-µL sample loop, a HP Hewlett Packard series
1050 UV detector operating at 254 nm and an SRI model 302 PeakSimple
Chromatography Data System six-channel recorder.
Analytical chromatography was carried out with a commercial Chiralcel OD-H
column (4.6 × 150 mm, available from Daicel Chemical Industries, LTD. Exton, PA.). All
solvents used were HPLC grade and used without further purification.
20 µL of each stock solution of analyte was injected into HPLC system. HPLC
conditions were as follows: mobile phase, hexane/2-propanol (4:1); flow rate, 2 mL/min;
column dimensions, 4.6 × 150 mm. The peak was monitored with UV-detector at λ = 254
nm. Each solution was measured three times, and the average value of these three tests
was used as the enantiomeric composition of analyte in the final solutions. The void time
was determined by recording the retention time of 1,3,5-tri-tert-butylbenzene at the same
condition.

Mass spectrometry
All mass spectra were obtained on a Micromass Quattro Micro (Beverly, MA)
triple quadrupole mass spectrometer with electrospray ionization running in the positive
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ion mode. Solutions were infused with a syringe pump into the ESI source at a rate of 20
µL/min. Spectrometer conditions were as follows: capillary voltage, 3.5 kV; cone voltage,
5.0 V; extractor voltage, 1.0 V; RF lens, 0.5 V; source temperature, 80°C; desolvation
temperature, 175°C; cone gas flow, 60 L/h; desolvation gas flow, 410 L/h. For each
sample of direct infusion, a full scan required about 1 s. The data collected over a 1-min
period were averaged to afford the final spectrum.

Results and Discussion
The chiral selectors studied in this chapter were based on the soluble analogues of
CSP 40 which was used in HPLC to separate β-blockers such as propranolol [106]. When
using CSP 40 in HPLC, (S)-propranolol was more retained on (R)-CPS 40, while
(R)-propranolol was more retained on (S)-CPS 40.
As mentioned above, the chiral recognition of β-blocker analyte and CSP 40 are
attributed to three main interactions between diastereomeric complex of the analyte and
selector. Due to the similarity of the newly designed chiral selectors 42, 43 and 44 to the
structure of CSP 40, the three interactions should be maintained and the chiral
recognition should be observed. Chiral selectors 42, 43 and 44 were prepared from
benzaldehyde or 4-substitued benzaldehyde (see Figure 4.5); each had a slightly different
mass due to the 4-substituted group. So a mixture of any two of them can be used as a
pair of mass-labeled pseudoenantiomers in ESI-MS.
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Figure 4.6: ESI-MS of solutions containing pseudoenantiomeric chiral selectors (R)-42,
(S)-43 and analyte 35.

First, the mass spectrometric experiment was performed using (R)-42 and (S)-43
as a pair of pseudoenantiomeric chiral selectors. A solution containing 1:1 mixture of
(R)-42 and (S)-43 was prepared as the stock solution. The final solution was made to
contain 1.0 mM in both (R)-42 and (S)-43, 0.2 mM in analyte 35, and 0.2 mM hydrogen
chloride as additive (since the analyte 35 was bought as hydrochloride salt, 1 equivalent).
The enantiomeric composition of analyte 35 in each solution was varied, and was
determined by HPLC. In each case the solvent was a mixture of methanol and water (1:1).
Positive ion mode electrospray ionization was performed on the solutions of chiral
selector (R)-42 and (S)-43, and analyte 35 (Figure 4.6). The ions of selector-analyte
complexes were observed in the mass spectrometry. This spectrum was obtained by
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infusing the sample into the spectrometer at a flow rate of 20 µL/min with a syringe
pump. The mass spectrum is extracted by averaging about 1 min of the total ion count
(TIC).
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Figure 4.7: Mass spectrum of a solution of pseudoenantiomeric selectors (R)-42 and
(S)-43 (1 mM for each) and racemic analyte 35 (0.2 mM) with hydrogen
chloride (0.2 mM) in water/methanol (1:1).

Figure 4.7 shows the full mass spectrum for the solution containing racemic
analyte 35, chiral selector (R)-42 and (S)-43 and hydrogen chloride as additive. The
monomeric ions of analyte [35 + H]+ and chiral selectors, [42 + Na]+ and [43 + Na]+, are
observed at m/z 260, 432, and 446, respectively. The dimeric ions of analyte are observed
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at m/z 519 [352 + H]+ and 541 [352 + Na]+. The dimeric ions of selectors are observed at
m/z 841 [422 + Na]+, 855 [42 + 43 + Na]+ and 869 [432 + Na]+. The analyte-selector
hetero-dimers, [42 + 35 + H]+ and [43 + 35 + H]+, are observed at m/z 669 and 683
respectively.
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Figure 4.8: Partial mass spectra of chiral selectors (R)-42 and (S)-43 (1.0 mM each),
analyte 35 (0.2 mM) with hydrogen chloride (0.2 mM) in methanol/water
(1:1). The enantiomeric compositions of analyte 35 are as follow: (a) 100%
(R)-35, (b) 76.28% (R)-35, (c) 50.15% (R)-35, (d) 29.55% (R)-35, and (e) 0%
(R)-35.
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Partial mass spectra of pseudoenantiomeric selectors (R)-42 and (S)-43, and
analyte 35 are shown in Figure 4.8. The enantiomeric compositions of analyte 35 in the
five solutions are as follow: (a) 100% (R)-35, (b) 76.28% (R)-35, (c) 50.15% (R)-35, (d)
29.55% (R)-35, and (e) 0% (R)-35. The relative intensities of the selector-analyte
complexes vary regularly with the enantiomeric composition of the analyte,
demonstrating chiral recognition. As the amount of (R)-35 is increased in the sample, the
complex with the (S)-43 selector is increased relative to the complex with the (R)-42
selector (m/z 683 vs m/z 669); likewise, as the amount of (S)-35 is increased in the sample,
the complex with the (R)-42 selector is increased relative to the complex with the (S)-43
selector.
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Figure 4.9: ESI-MS of solutions containing pseudoenantiomeric chiral selectors (R)-44,
(S)-43 and analyte 35.
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In the same manner, the compound (R)-44 and (S)-43 were tested as the
pseudoenantiomeric chiral selectors (Figure 4.9). Figure 4.10 shows the full mass
spectrum for the solution containing chiral selector (R)-44, (S)-43 and racemic analyte 35.
This spectrum is very similar to what obtained using (R)-42 and (S)-43 as a pair of
pseudoenantiomeric chiral selectors (Figure 4.7). The analyte-selector hetero-dimers, [43
+ 35 + H]+ and [44 + 35 + H]+, are observed at m/z 683 and 699 respectively.
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Figure 4.10: Mass spectrum of a solution of pseudoenantiomeric selectors (R)-44 and
(S)-43 (1 mM for each) and racemic analyte 35 (0.2 mM) with hydrogen
chloride (0.2 mM) in water/methanol (1:1).
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Figure 4.11: Partial mass spectra of chiral selectors (R)-44 and (S)-43 (1.0 mM each),
analyte 35 (0.2 mM) and hydrogen chloride (0.2 mM) in methanol/water
(1:1). The enantiomeric compositions of analyte 35 are as follow: (a) 100%
(R)-35, (b) 76.28% (R)-35, (c) 50.15% (R)-35, (d) 29.55% (R)-35 and (e)
0% (R)-35.

Figure 4.11 shows the partial mass spectra containing the complexes between
pseudoenantiomeric selectors (R)-44 and (S)-43, and analyte 35 with hydrogen chloride
as additive. When the sample is enriched in the (R)-analyte 35, the relative intensity of
the complex between selector (S)-43 and analyte 35 (m/z 683) in the mass spectrum is
increased with respect to the complex between selector (R)-44 and analyte 35 (m/z 699),
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while the sample is enriched with the (S)-analyte 35, the relative intensity of the complex
between selector (R)-44 and analyte 35 (m/z 699) is increased with respect to the complex
between selector (S)-43 and analyte 35 (m/z 683).
In both of the two tests (pseudoenantiomer pair (R)-42/(S)-43, and pair
(R)-44/(S)-43), the chiral recognition between the phosphonate ester chiral selectors (42,
43, and 44) and analyte 35 is observed in the positive ion mode ESI-MS. As the amount
of the (R)-analyte is increased in the sample, the relative intensity of the complex
between (S)-selector and analyte is increased. Likewise, the increase in amount of
(S)-analyte gives an increase in the peak intensity of complex between (R)-selector and
analyte. This is consistent with observed elution order of propranolol in HPLC using CSP
40: if of the R configuration, it should retain the S enantiomer of a β-blocker; if of the S
configuration, it should retain the R enantiomer of a β-blocker.
For each set of data, a plot of the complex intensity fraction (CIF) versus the mole
fraction of the (R)-35 in the solution for five different enantiomeric compositions are
obtained as shown in Figure 4.12. Each plot is linear with the correlation coefficient of
0.995 (for (R)-42/(S)-43 pair) and 0.998 (for (R)-44/(S)-43 pair) respectively. These plots
with linear relationship provide a simple method for determining the enantiomeric
composition of the propranolol. Simply measuring the CIF of the selector-analyte
complexes in the mass spectrum with constant conditions and applying this value to the
calibration line affords the enantiomeric composition of the analyte. According to the
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Equation 1.3, the αMS is calculated to be 1.12 (for (R)-42/(S)-43 pair) and 1.07 (for
(R)-44/(S)-43 pair). The pair of (R)-42/(S)-43 gives the better enantioselectivity with αMS
= 1.12, although both of enantioselectivity (αMS) are smaller than that obtained by HPLC.
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Figure 4.12: Plots of the complex intensity fraction (CIF) for the selector-analyte
complexes in the ESI-MS versus the mole fraction of (R)-35 in the solution,
using pseudoenantiomeric chiral selectors (R)-42/(S)-43 (slope = 0.0556, r2
= 0.995, α = 1.12) and (R)-44/(S)-43 (slope = 0.0358, r2 = 0.998, α = 1.07).

The enantioselectivity of these phosphonate ester chiral selectors was also tested
by different additives. Since propranolol (35) was bought as hydrochloride salt (1
equivalent), the experiments carried out initially with the hydrogen chloride as additive
with the same concentration as the analyte. Then the hydrochloride portion of the original
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analyte was removed by running an aluminum oxide column chromatography using
methanol as the mobile phase to afford pure R and S propranolol. The tests of different
additives were performed only to the pseudoenantiomer pair (R)-42/(S)-43, which has the
better enantioselectivity (αMS) than the other pair in the first study. Three stock solutions
of propranolol (35) without hydrochloride portion were prepared to be 100% (R)-35, 50%
(R)-35 and 0% (R)-35 in methanol. The exact enantiomeric composition of each stock
solution measured by HPLC was as follow: 100% (R)-35, 53.92% (R)-35 and 0% (R)-35.
The stock solution of pseudoenantiomeric selectors (R)-42 and (S)-43, was also prepared
in methanol at 5 mM, respectively. Stock solutions of different additives (NH4Cl, HOAc
and HCOOH) were made in water at 2 mM. The concentration for each final solution was
1.0 mM for each chiral selector, 0.2 mM for analyte and 0.2 mM for additive in
water/methanol (1:1). ESI-MS experimental conditions stayed the same as previous runs.
The analyte-selector complex in each test can be observed clearly in ESI-MS. The
sense of chiral recognition was consistent with the spectra shown previously. To compare
the enantioselectivity, plots of the complex intensity fraction (CIF) versus the mole
fraction of the (R)-35 in the series of solution for different additives are obtained as
shown in Figure 4.13. Each plot is linear with the correlation coefficient of 0.998 (for
additive NH4Cl), 0.993 (for additive HOAc) and 0.993 (for additive HCOOH)
respectively. According to the Equation 1.3, the αMS is calculated to be 1.13 (for additive
NH4Cl), 1.08 (for additive HOAc) and 1.10 (for additive HCOOH) respectively. These
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results are very close to the αMS using HCl as additive (αMS = 1.12), indicating that the
influence by these additives to the enantioselectivity is small. All the chiral recognitions
are consistent with the chromatographic data.
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Figure 4.13: Plots of CIF versus the mole fraction of (R)-35 (100% (R)-35, 53.92%
(R)-35 and 0% (R)-35, determined by HPLC) using pseudoenantiomeric
chiral selectors (R)-42 and (S)-43 with different additives. For NH4Cl
additive, slope = 0.0597, r2 = 0.998, α = 1.13; for HOAc additive, slope =
0.0389, r2 = 0.993, α = 1.08; and for HCOOH additive, slope = 0.0480, r2 =
0.993, α = 1.10.

Conclusion
The use of phosphonate ester 42, 43 and 44 as pseudoenantiomer for the
determination of enantiomeric composition of propranolol by ESI-MS is demonstrated
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above. The chiral selectors used in this study were derived from the CSP 40, which was
used for the enantioseparation of β-blocker in HPLC [106,109]. Solutions containing a
pair of pseudoenantiomeric chiral selectors and analyte afford protonated selector-analyte
complexes in the positive ion mode electrospray ionization mass spectrum, and the
relative peak intensities of the complexes can be related back to the enantiomeric
composition of the analyte. According to the ESI-MS data, the peak intensity of complex
between (R)-selector and analyte increased relatively as the increase of (S)-analyte in the
sample, while the peak intensity of complex between (S)-selector and analyte increased
relatively as the increase of (R)-analyte in the sample, i.e., in ESI-MS the (R)-selector
retained the (S)-analyte, while the (S)-selector retained the (R)-analyte. This is consistent
with the observation by HPLC using CSP 40. Reported by Pirkle and coworkers [106], in
HPLC, if use the (R)-CSP 40, the (R)-propranolol comes out first, indicating the (R)-CSP
40 retains S enantiomer of propranolol.
Although the enantioselectivity of ESI-MS (αMS = 1.07-1.12) is lower than that of
HPLC (αHPLC), this ESI-MS method has its own potential for rapid chiral analysis since
each single measurement by this ESI-MS method currently can be done within 1 min,
whereas traditional chromatographic measurements require a relatively long time.
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CHAPTER V
CONCLUSIONS

In summary, the work in this thesis has demonstrated the chiral recognition
through the adaptation of chromatographically derived chiral recognition systems by
electrospray

ionization

mass

spectrometry

(ESI-MS).

Mass-labeled,

pseudo-

enantiomeric chiral selectors (where each pseudoenantiomer has the opposite
stereochemistry, but a slightly different mass due to labeling of one enantiomer at a
remote position from the chiral recognition site) were prepared as soluble analogues of
Pirkle type chiral stationary phases used in HPLC. When mixed with a chiral analyte,
solutions containing these pseudoenantiomeric selectors afford selector-analyte
complexes in the ESI-MS, and the relative peak intensities of the complexes can be
related back to the enantiomeric composition of the analyte. In each case in this study, the
complex intensity fraction (CIF) for either of the selector-analyte complexes in the
ESI-MS varies linearly with the enantiomeric composition of the analyte. This linear
relationship provides a measure of the extent of enantioselectivity and allows quantitative
enantiomeric analysis.
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All the chiral selectors studied in this thesis are derived from well-established
Pirkle type CSPs used in HPLC. Since the similarity in structure of these newly
developed chiral selectors to the Pirkle type CSPs, the chiral recognition mechanism for
these new selectors for analytes mainly involves: (a) the π-π interaction between the
π-acidic DNB group of the selector and the π-basic aromatic group of the analyte; (b) the
hydrogen bond between the DNB amide proton of the selector and the carbonyl group of
the analyte. Besides, as we mentioned in each chapter, different pairs of selector and
analyte may have additional π-π interaction or hydrogen bond which also contributes to
the chiral recognition. Additionally, the sense of the observed chiral recognition using the
newly developed selectors by ESI-MS is in agreement with the sense of chiral
recognition observed chromatographically using the corresponding Pirkle type CSPs in
HPLC.
Although the enantioselectivity of ESI-MS (αMS) is lower than that obtained from
HPLC (αHPLC) using the corresponding Pirkle type CSPs, this ESI-MS method has its
own potential for rapid chiral analysis because each single measurement by this ESI-MS
method currently can be done within 1 min, whereas traditional chromatographic
measurements require a relatively long time. Since the large number of known CSPs, and
the scope of chiral analytes for each, adaptation of these chiral selectors into
corresponding mass spectrometric chiral selectors could expand the set of chiral analytes
that can be analyzed by this ESI-MS method [58]. Additionally, such a rapid throughput
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method would be an invaluable tool for the evaluation of potential chiral catalysts and for
the discovery of new chiral selectors, especially for the screening of combinatorial
libraries of potential chiral selectors.
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